<SEC-DOCUMENT>0001193125-25-028691.txt : 20250218
<SEC-HEADER>0001193125-25-028691.hdr.sgml : 20250218
<ACCEPTANCE-DATETIME>20250218165236
ACCESSION NUMBER:		0001193125-25-028691
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20250218
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250218
DATE AS OF CHANGE:		20250218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Solid Biosciences Inc.
		CENTRAL INDEX KEY:			0001707502
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				900943402
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38360
		FILM NUMBER:		25635867

	BUSINESS ADDRESS:	
		STREET 1:		500 RUTHERFORD AVENUE
		STREET 2:		3RD FLOOR
		CITY:			CHARLESTOWN
		STATE:			MA
		ZIP:			02129
		BUSINESS PHONE:		617-337-4680

	MAIL ADDRESS:	
		STREET 1:		500 RUTHERFORD AVENUE
		STREET 2:		3RD FLOOR
		CITY:			CHARLESTOWN
		STATE:			MA
		ZIP:			02129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Solid Biosciences, LLC
		DATE OF NAME CHANGE:	20170524
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d908068d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sldb="http://www.solidbio.com/20250218" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-341">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-02-18_to_2025-02-18">0001707502</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="sldb-20250218.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-02-18_to_2025-02-18"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-18</xbrli:startDate> <xbrli:endDate>2025-02-18</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-352">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt:datemonthdayyearen" id="ixv-353">February 18, 2025</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-354">Solid Biosciences Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:stateprovnameen" id="ixv-355">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-356">001-38360</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-357">90-0943402</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:99%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-358">500 Rutherford Avenue</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-359">Third Floor</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-360">Charlestown</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:stateprovnameen" id="ixv-361">Massachusetts</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-362">02129</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices) (Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-363">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-364">337-4680</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="font-style:italic">see</span> General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:boolballotbox" id="ixv-365">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:boolballotbox" id="ixv-366">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:boolballotbox" id="ixv-367">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:boolballotbox" id="ixv-368">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-369">Common Stock $0.001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-370">SLDB</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:exchnameen" id="ixv-371">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company &#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:boolballotbox" id="ixv-372">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry Into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;18, 2025, Solid Biosciences Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), relating to an underwritten public offering of 35,739,810 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), and, in lieu of Common Stock to certain investors, <span style="white-space:nowrap">pre-funded</span> warrants (the <span style="white-space:nowrap">&#8220;Pre-Funded</span> Warrants&#8221;) to purchase 13,888,340 shares of Common Stock (the &#8220;Warrant Shares&#8221;). All of the Shares and the <span style="white-space:nowrap">Pre-Funded</span> Warrants are being sold by the Company. The offering price of the Shares is $4.03 per share and the offering price of the <span style="white-space:nowrap">Pre-Funded</span> Warrants is $4.029 per share underlying each <span style="white-space:nowrap">Pre-Funded</span> Warrant. The Underwriters have agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $3.7882 per share and the <span style="white-space:nowrap">Pre-Funded</span> Warrants from the Company pursuant to the Underwriting Agreement at a price of $3.7872 per share underlying each <span style="white-space:nowrap">Pre-Funded</span> Warrant. The closing of the offering is expected to take place on or about February&#160;19, 2025, subject to the satisfaction of customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates that the net proceeds from the offering will be approximately $187.5&#160;million, after deducting underwriting discounts and commissions and estimated offering expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares and the <span style="white-space:nowrap">Pre-Funded</span> Warrants will be issued pursuant to a shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-277871)</span> that was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on May&#160;17, 2024. A prospectus supplement relating to the offering has been filed with the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <span style="white-space:nowrap">Pre-Funded</span> Warrant has an exercise price per share of Common Stock equal to $0.001 per share. Each <span style="white-space:nowrap">Pre-Funded</span> Warrant will be exercisable at any time from the date of issuance. The <span style="white-space:nowrap">Pre-Funded</span> Warrants will be exercisable, at the option of each holder, in whole or in part, by means of a cash exercise or a cashless exercise. The exercise price and the number of shares of Common Stock issuable upon exercise of each <span style="white-space:nowrap">Pre-Funded</span> Warrant is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the <span style="white-space:nowrap">Pre-Funded</span> Warrants, the Company may not effect the exercise of any <span style="white-space:nowrap">Pre-Funded</span> Warrant, and a holder will not be entitled to exercise any portion of any <span style="white-space:nowrap">Pre-Funded</span> Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) to exceed 4.99% or 9.99%, as elected by the holder, of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the <span style="white-space:nowrap">Pre-Funded</span> Warrant, which percentage may be changed at the holder&#8217;s election to a higher percentage not in excess of 19.99% upon 61 days&#8217; notice to the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in certain circumstances, upon a fundamental transaction, a holder of <span style="white-space:nowrap">Pre-Funded</span> Warrants will be entitled to receive, upon exercise of the <span style="white-space:nowrap">Pre-Funded</span> Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the <span style="white-space:nowrap">Pre-Funded</span> Warrants immediately prior to the fundamental transaction, without regard to any limitations on exercise contained in the <span style="white-space:nowrap">Pre-Funded</span> Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the terms of the Underwriting Agreement and the <span style="white-space:nowrap">Pre-Funded</span> Warrants do not purport to be a complete and are qualified in their entirety by reference to the Underwriting Agreement and the Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant which are filed as Exhibit 1.1 and Exhibit 4.1 hereto, respectively, and are incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the legal opinion and consent of Wilmer Cutler Pickering Hale and Dorr LLP relating to the Shares, the <span style="white-space:nowrap">Pre-Funded</span> Warrants and the Warrant Shares is filed as Exhibit 5.1 hereto. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;18, 2025, the Company issued a press release announcing the pricing of the offering. A copy of the press release has been filed as Exhibit&#160;99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cautionary Note Regarding Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains &#8220;forward-looking statements&#8221; within the meaning of The Private Securities Litigation Reform Act of 1995, such as those, among others, relating to the expected closing of the offering. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements the Company makes as a result of various risks and uncertainties, including but not limited to, market and other financial conditions, the satisfaction of customary closing conditions related to the offering and the impact of general economic, industry or political conditions in the United States or internationally. Additional risks and uncertainties relating to the offering, the Company and its business can be found under the caption &#8220;Risk Factors&#8221; included in the Company&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ended September&#160;30, 2024, the Company&#8217;s prospectus supplement filed with the SEC on February&#160;18, 2025, and other filings that the Company may make with the SEC in the future. In addition, the forward-looking statements included in this Current Report on Form <span style="white-space:nowrap">8-K</span> represent the Company&#8217;s views as of the date hereof and should not be relied upon as representing the Company&#8217;s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company&#8217;s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d908068dex11.htm">Underwriting Agreement, dated February&#160;18, 2025, by and among the Company and Jefferies LLC and Leerink Partners LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d908068dex41.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d908068dex51.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d908068dex51.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (contained in Exhibit&#160;5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d908068dex991.htm">Press Release dated February&#160;18, 2025 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">SOLID BIOSCIENCES&#160;INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: February&#160;18, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Alexander Cumbo</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Alexander Cumbo</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d908068dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SOLID BIOSCIENCES INC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35,739,810
Shares of Common Stock, Par Value $0.001 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase 13,888,340 Shares of Common Stock </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Underwriting Agreement </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">February&nbsp;18, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters listed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in <U>Schedule 1</U> hereto </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 State Street, 40<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02109 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solid Biosciences Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several underwriters listed
in <U>Schedule 1</U> hereto (the &#147;<B>Underwriters</B>&#148;), for whom you are acting as representatives (the &#147;<B>Representatives</B>&#148;), (i) an aggregate of 35,739,810 shares of common stock, par value $0.001 per share, of the Company
(the &#147;<B>Shares</B>&#148;) and <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-funded</FONT> warrants to purchase an aggregate of 13,888,340 shares of common stock of the Company, at an exercise price equal to $0.001 per share, in the form
attached hereto as <U>Exhibit C</U> (the &#147;<B>Warrants</B>&#148;). The Shares and the Warrants are herein referred to as the &#147;<B>Securities</B>.&#148; The shares of common stock of the Company issuable upon exercise of the Warrants are
herein referred to as the &#147;<B>Warrant Shares</B>.&#148; The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares and the exercise of the Warrants are referred to herein as the
&#147;<B>Stock</B>.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Underwriters concerning the
purchase and sale of the Securities, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Registration Statement</U>. The Company has prepared and filed with the Securities
and Exchange Commission (the &#147;<B>Commission</B>&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;<B>Securities Act</B>&#148;), a registration statement on
Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-277871),</FONT> including a prospectus, relating to the Securities and the Warrant Shares. Such registration statement, as amended at the time it
became effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#147;<B>Rule 430 Information</B>&#148;), is referred
to herein as the &#147;<B>Registration Statement</B>&#148;; and as used herein, the term &#147;<B>Preliminary Prospectus</B>&#148; means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any
prospectus filed with the Commission pursuant to Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information (the &#147;<B>Base
Prospectus</B>&#148;), and the term &#147;<B>Prospectus</B>&#148; means the Base Prospectus and the prospectus supplement relating to the Securities and the Warrant in the form first used (or made available upon request of purchasers pursuant to
Rule 173 under the Securities Act) in connection with confirmation of sales of the Securities. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the &#147;<B>Rule 462 Registration
Statement</B>&#148;), then any reference herein to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this &#147;<B>Agreement</B>&#148;) to the
Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities
Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be, and any reference to &#147;amend&#148;, &#147;amendment&#148; or &#147;supplement&#148; with respect to the
Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission
thereunder (collectively, the &#147;<B>Exchange Act</B>&#148;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the
Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below), the Company had prepared the following information (collectively with
the pricing information set forth on <U>Annex A</U>, the &#147;<B>Pricing Disclosure Package</B>&#148;): the Base Prospectus dated February&nbsp;18, 2025 and each &#147;free-writing prospectus&#148; (as defined pursuant to Rule 405 under the
Securities Act) listed on <U>Annex A</U> hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Applicable Time</B>&#148; means 7:00 A.M., New York City time, on
February&nbsp;18, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase of the Securities</U>. (a)&nbsp;The Company agrees to issue and sell the Securities to the several
Underwriters as provided in this Agreement, and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a
price per share of $3.7882 (the &#147;<B>Share Purchase Price</B>&#148;) from the Company the respective number of Shares set forth opposite such Underwriter&#146;s name in <U>Schedule 1</U> hereto, and to purchase at a price of $3.7872 per Warrant
(the &#147;<B>Warrant Purchase Price</B>&#148;) from the Company the respective number of Warrants set forth opposite such Underwriter&#146;s name in <U>Schedule 1</U> hereto. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company understands that the Underwriters intend to make a public offering of the
Securities, and initially to offer the Securities on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Securities to or through any affiliate of an Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Payment for the Securities shall be made by wire transfer in immediately available funds to the account specified by the Company to the
Representatives at the offices of Davis Polk&nbsp;&amp; Wardwell LLP, 450 Lexington Avenue, New York, New York 10017 at 10:00 A.M., New York City time, on February&nbsp;19, 2025, or at such other time or place on the same or such other date, not
later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing. The time and date of such payment for the Shares and Warrants is referred to herein as the &#147;<B>Closing Date</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for the Securities to be purchased on the Closing Date shall be made against delivery to the Representatives for the respective
accounts of the several Underwriters of the Securities to be purchased on such date with any transfer taxes payable in connection with the sale of such Securities to the Underwriters duly paid by the Company, as applicable. Delivery of the Shares
shall be made through the facilities of The Depository Trust Company (&#147;<B>DTC</B>&#148;) unless the Representatives shall otherwise instruct. The Warrants shall be delivered to the purchasers of the Warrants (or to the Representatives as
directed by the Representatives), in definitive form, registered in such names and in such denominations as the Representatives shall request in writing no later than one business day prior to the Closing Date. The Warrants will be made available
for inspection by the Representatives on the business day prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Company and the
Representatives shall instruct the purchasers of the Warrants in the public offering to make payment for the Warrants on the Closing Date to the Company by wire transfer in immediately available funds to the account specified by the Company at a
purchase price of $4.029 per Warrant in lieu of payment by the Underwriters for such Warrants, and the Company shall deliver such Warrants to such purchasers on the Closing Date in definitive form against such payment in lieu of the Company&#146;s
obligation to deliver such Warrants to the Underwriters. The Company shall promptly (but in no event later than the Closing Date) pay $0.2418 per warrant (the &#147;<B>Warrant Underwriting Discount</B>&#148;) to the Representatives by wire transfer
in immediately available funds to the account specified by the Representatives, <I>provided</I>, <I>however</I>, that the Company agrees that the Representatives will be entitled at their discretion to set off the payment for the Shares against the
aggregate Warrant Underwriting Discount payable to the Representatives, and any excess amount will remain due and payable to the Company on the Closing Date. In the event the purchasers of the Warrants in the offering fail to make payment to the
Company for all or part of the Warrants on the Closing Date, the Underwriters agree to make payment to the Company for such Warrants at a price per Warrant equal to the Warrant Purchase Price; <I>provided</I>, <I>however</I>, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">that the Representatives may elect, by written notice to the Company, to receive shares of common stock of
the Company in lieu of all or a portion of such Warrants to be delivered to the Underwriters under this Agreement at a price per share equal to the Share Purchase Price (the &#147;<B>Substitute Shares</B>&#148;). The aggregate amount of Substitute
Shares and Warrants to be delivered to the Representatives hereunder may be reallocated at the discretion of the Representatives no later than the business day prior to the Closing Date, to increase or decrease the number of Substitute Shares or
Warrants, <I>provided</I> that the aggregate number of Substitute Shares and Warrants issued does not exceed 49,628,150. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company
acknowledges and agrees that the Representatives and the other Underwriters are acting solely in the capacity of an arm&#146;s length contractual counterparty to the Company with respect to the offering of Securities contemplated hereby (including
in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company
or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation
and appraisal of the transactions contemplated hereby, and neither the Representatives nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto. Any review by the Representatives and the other
Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Preliminary Prospectus</I>. No order preventing or suspending the use of any Preliminary Prospectus has been issued by
the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the applicable requirements of the Securities Act, and no Preliminary Prospectus
included in the Pricing Disclosure Package, at the time of filing thereof, contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <I>provided</I> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter
furnished to the Company in writing by such Underwriter through the Representatives expressly for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the
information described as such in Section&nbsp;7(b) hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of
the Applicable Time did not, and as of the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading; <I>provided</I> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company
in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such
in Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included
in the Prospectus has been omitted therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Issuer Free Writing Prospectus. </I>Other than the Registration
Statement, any Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not
prepare, make, use, authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication
by the Company or its agents and representatives (other than a communication referred to in clause (i)&nbsp;below) an &#147;<B>Issuer Free Writing Prospectus</B>&#148;) other than (i)&nbsp;any document not constituting a prospectus pursuant to
Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on <U>Annex A</U> hereto, each electronic road show and any other written communications approved in writing in advance by the
Representatives, which approval shall not be unreasonably withheld, delayed or conditioned. Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in
Rule 433 under the Securities Act) filed in accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken
together with any Preliminary Prospectus accompanying, or delivered prior to delivery of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date will not, contain any untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided</I> that the Company makes no representation or warranty with respect to any statements or omissions
made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly
for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials. </I>The
Company (i)&nbsp;has not alone engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications (as defined below) in connection with the offering to which this Agreement relates other
than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the consent of the Representatives (x)&nbsp;with entities that are qualified institutional buyers (&#147;<B>QIBs</B>&#148;)
within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501(a)(1), (a)(2), </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)(3), (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act
(&#147;<B>IAIs</B>&#148;) and otherwise in compliance with the requirements of Section&nbsp;5(d) of the Securities Act or (y)&nbsp;with entities that the Company reasonably believed to be QIBs or IAIs and otherwise in compliance with the
requirements of Rule 163B under the Securities Act and (ii)&nbsp;has not authorized anyone other than the Representatives to engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications.
The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. &#147;<B><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications</B>&#148; means any communication with potential investors undertaken in reliance on Section&nbsp;5(d) or Rule 163B of the Securities Act.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Registration Statement and Prospectus.</I> The Registration Statement has been declared effective by the
Commission. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering
of the Securities has been initiated, or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any
such post-effective amendment complied and will comply in all material respects with the applicable requirements of the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date, the Prospectus will comply in all material
respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading; <I>provided</I> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by
such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Incorporated Documents.</I> The
documents incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of
such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so
filed and incorporated by reference in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and
will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Financial Statements.</I> The financial statements (including the
related notes thereto) of the Company and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable
requirements of the Securities Act and present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows
for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles (&#147;<B>GAAP</B>&#148;) in the United States applied on a consistent basis throughout the periods covered thereby,
except unaudited financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission, and any supporting schedules
included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein; and the other financial information to the extent included or incorporated by reference in the
Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly the information shown thereby in all material respects; all
disclosures included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus regarding <FONT STYLE="white-space:nowrap">&#147;non-GAAP</FONT> financial measures&#148; (as such term is defined by
the rules and regulations of Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the Securities Act, to the extent applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>No Material Adverse Change.</I> Since the date of the most recent financial statements of the Company included or
incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any material change in the capital stock (other than the issuance of shares of common stock upon exercise of
stock options and warrants and the vesting of restricted stock units described as outstanding in, and the grant of options, restricted stock units and other awards under existing equity incentive plans described or incorporated by reference in, the
Registration Statement, the Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the
Company on any class of capital stock, or any material adverse change, or any development that would reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position,
stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii)&nbsp;neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the
ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and
(iii)&nbsp;neither the Company nor any of its subsidiaries has sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, pandemic, flood or
other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the
Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Organization and Good Standing.</I> The Company and each of its
subsidiaries have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their
respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they
are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties,
management, financial position, stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#147;<B>Material
Adverse Effect</B>&#148;). The subsidiaries listed in Exhibit 21.1 to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023 are the only subsidiaries of the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Capitalization.</I> The Company has an authorized capitalization as set forth in the Registration Statement, the
Pricing Disclosure Package and the Prospectus under the heading &#147;Capitalization&#148;; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights that have not been duly waived or satisfied; except as described in or expressly contemplated by the
Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights that have not been duly waived or satisfied),
warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement
of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material
respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or
indirectly, by the Company have been duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (except, as otherwise described in the Registration Statement, the Pricing Disclosure Package and
the Prospectus), and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Equity Awards. </I>With respect to the equity awards (the
&#147;<B>Equity Awards</B>&#148;) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries outstanding on the date hereof (the &#147;<B>Company Stock Plans</B>&#148;), (i) each Equity Award that consisted of options
to purchase shares of stock of the Company intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;) so qualifies, (ii)&nbsp;each grant of an
Equity Awards was duly authorized no later than the date on which the grant of such Equity Awards was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a
duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party
thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all other applicable laws and regulatory rules or requirements, including the rules of the Nasdaq Global Select Market and any
other exchange on which Company securities are traded, and (iv)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company and disclosed in the Company&#146;s
filings with the Commission in accordance with the Exchange Act and all other applicable laws. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company of granting, Equity Awards prior to, or otherwise
coordinating the grant of Equity Awards with, the release or other public announcement of material information regarding the Company or its subsidiaries or their results of operations or prospects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Due Authorization.</I> The Company has the requisite, power and authority to execute and deliver this Agreement and to
perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly
taken, and this Agreement has been duly authorized, executed and delivered by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>The Securities and the
Warrant Shares</I>. (i)&nbsp;The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and
nonassessable and will conform in all material respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus ; (ii) the Warrants have been duly authorized by the Company and, when executed and
delivered by the Company in accordance with this Agreement, will constitute valid and legally binding agreements of the Company, enforceable against the Company in accordance with their terms, except as enforceability may be limited by applicable
bankruptcy, insolvency or similar laws affecting creditors&#146; rights generally or by equitable principles relating to enforceability; (iii)&nbsp;the Warrant Shares to be issued by the Company upon exercise of the Warrants, as provided therein,
have been duly and validly authorized and, when issued and delivered upon exercise as provided under the Warrants, will be duly and validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will conform in all
material respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and (iv)&nbsp;the issuance of the Securities and the Warrant Shares is not subject to any preemptive or similar rights
that have not been duly waived or satisfied. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Description of the Underwriting Agreement</I>. This Agreement
conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>No Violation or Default.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or <FONT
STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any
term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound
or to which any property or asset of the Company or any of its subsidiaries is subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority,
except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>No Conflicts. </I>The execution, delivery and performance by the Company of this Agreement and the Warrants, the
issuance and sale of the Securities and the Warrant and the consummation of the transactions contemplated by this Agreement and the Warrants or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict with or result in a breach
or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or
asset of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its
subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar
organizational documents of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in
the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>No Consents Required.</I> No consent, approval, authorization, order, registration or qualification of or with any court
or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Securities and the consummation of the transactions contemplated by this
Agreement, except for the registration of the Securities under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by FINRA, the Nasdaq Stock Market and under applicable
state securities laws in connection with the purchase and distribution of the Securities by the Underwriters. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>Legal Proceedings.</I> Except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#147;<B>Actions</B>&#148;) pending to which the
Company or any of its subsidiaries is or may reasonably be expected to become a party or to which any property of the Company or any of its subsidiaries is or reasonably expects to be the subject that, individually or in the aggregate, if determined
adversely to the Company or any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or
threatened by others; and (i)&nbsp;there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration
Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>Independent Accountants</I>. PricewaterhouseCoopers LLP, who have certified certain financial
statements of the Company and its subsidiaries, is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company
Accounting Oversight Board (United States) and as required by the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>Title to Real and Personal
Property</I>. The Company and its subsidiaries have good and marketable title in fee simple to (in the case of real property), or have valid rights to lease or otherwise use, all items of real and personal property that are material to the
respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to
be made of such property by the Company and its subsidiaries or (ii)&nbsp;would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>Title to Intellectual Property</I>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, the Company and its subsidiaries own or license valid and enforceable rights to use all inventions, patent rights, trademarks, service marks, trade names, trade dress, domain names, copyrights, licenses, <FONT
STYLE="white-space:nowrap">know-how,</FONT> trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures and all similar intellectual property and proprietary rights (including all
registrations and applications for registration of, and all goodwill associated with, any of the foregoing, as applicable) (collectively, &#147;<B>Intellectual Property</B>&#148;) described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus as being owned by or licensed to the Company and its subsidiaries, and all other Intellectual Property used in or reasonably necessary for the conduct of their </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
business as currently conducted and as proposed to be conducted in the Registration Statement, Pricing Disclosure Package or the Prospectus. Except as disclosed in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, the conduct of the business of the Company and its subsidiaries does not, and the proposed conduct of such business as disclosed in the Registration Statement, Pricing Disclosure Package or the
Prospectus will not, infringe, misappropriate or otherwise violate any Intellectual Property rights of any others. Except as described in the Registration Statement, Pricing Disclosure Package or the Prospectus, there is no pending or, to the
Company&#146;s knowledge, threatened action, suit, proceeding or claim by any others (i)&nbsp;that the Company or any of its subsidiaries infringes, misappropriates or otherwise violates the Intellectual Property of others, or (ii)&nbsp;challenging
the validity, enforceability, scope or ownership of any Intellectual Property owned by or licensed to the Company or any of its subsidiaries or their rights therein. To the knowledge of the Company, no third party has infringed, misappropriated or
otherwise violated any Intellectual Property owned by or exclusively licensed to the Company or any of its subsidiaries. To the Company&#146;s knowledge, none of the Intellectual Property used by the Company or any of its subsidiaries in the conduct
of its business has been obtained or is being used by the Company or any of its subsidiaries in material violation of any contractual obligation binding on the Company or any of its subsidiaries. Except as set forth in the Registration Statement,
Pricing Disclosure Package or the Prospectus, the Intellectual Property owned by the Company and its subsidiaries is all solely owned by the Company or its subsidiaries free and clear of any liens or encumbrances. To the Company&#146;s knowledge, no
trademark, issued patent, pending patent application (if issued), copyright, or trade secret that is described in the Registration Statement, Pricing Disclosure Package or Prospectus as being owned by or licensed to the Company or any of its
subsidiaries is invalid or unenforceable. Neither the Company nor any of its subsidiaries is subject to any judgment, order, writ, injunction or decree of any court or any federal, state, local, foreign or other governmental department, commission,
board, bureau, agency or instrumentality, domestic or foreign, or any arbitrator, nor has it entered into or is a party to any agreement made in settlement of any pending or threatened litigation, which materially restricts or impairs its use of any
Intellectual Property. The Company and its subsidiaries have taken all commercially reasonable steps, in accordance with normal industry practice, necessary to maintain the confidentiality of all Intellectual Property the value of which to the
Company or any of its subsidiaries is contingent upon maintaining the confidentiality thereof, except as would not reasonably be expected to have a Material Adverse Effect, and neither the Company nor any of its subsidiaries is aware of any material
disclosure of such Intellectual Property other than to employees, representatives, independent contractors, collaborators, licensors, licensees, agents and advisors of the Company and its subsidiaries and any other third parties, all of whom are
bound by written obligations to maintain the confidentiality thereof. All founders, key employees and any other employees involved in the development of Intellectual Property for the Company and its subsidiaries have signed confidentiality and
invention assignment agreements or similar agreements for the transfer, assignment, and/or licensing of Intellectual Property with the Company and its subsidiaries pursuant to which the Company and its subsidiaries either (i)&nbsp;have obtained
ownership of and are the exclusive owners of, or (ii)&nbsp;have obtained a valid and unrestricted right to exploit, sufficient for the conduct of their business, such Intellectual Property. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>No Undisclosed Relationships</I>. No relationship, direct or
indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries, on the other, that is required
by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <I>Investment Company Act</I>. The Company is not and, immediately after giving effect to the offering and sale of the
Securities and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#147;investment company&#148; or an entity
&#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;<B>Investment Company
Act</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>Taxes.</I> The Company and its subsidiaries have paid all federal, state, local and foreign taxes
and filed all tax returns required to be paid or filed through the date hereof; and except as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no tax deficiency that has been, or
could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets that would reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <I>Licenses and Permits.</I> The Company and its subsidiaries possess all licenses,
<FONT STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities
that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the
failure to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and except as described in each of the Registration Statement, the Pricing Disclosure Package and the
Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation or material modification of any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization or has any
reason to believe that any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization will not be renewed in the ordinary course, except where such revocation, modification or <FONT
STYLE="white-space:nowrap">non-renewal</FONT> would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <I>No Labor Disputes.</I> No labor disturbance by or dispute with employees of the Company or any of its subsidiaries
exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries&#146; principal suppliers,
contractors or customers, except as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of cancellation or termination with respect to any collective bargaining
agreement to which it is a party. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <I>Certain Environmental Matters</I>. (i)&nbsp;The Company and its
subsidiaries (x)&nbsp;are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally
enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;<B>Environmental
Laws</B>&#148;); (y) have received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses;
and (z)&nbsp;have not received notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release
of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;there are no costs or liabilities associated with
Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect; and (iii)&nbsp;except as described in each of the Pricing Disclosure Package and the Prospectus, (x)&nbsp;there is no proceeding that is pending, or that is known to be contemplated, against the Company or any of its subsidiaries under any
Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company and its subsidiaries are not
aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be
expected to have a material effect on the capital expenditures, earnings or competitive position of the Company and its subsidiaries, and (z)&nbsp;none of the Company or its subsidiaries anticipates a material increase in capital expenditures
relating to any Environmental Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <I>Compliance with ERISA</I>. (i)&nbsp;Each employee benefit plan, within the
meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#147;<B>ERISA</B>&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any entity, whether or not incorporated,
that is under common control with the Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the Code) would have
any liability (each, a &#147;<B>Plan</B>&#148;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code, except for
noncompliance that would not reasonably be expected to result in material liability to the Company; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption that would not reasonably be expected to
result in material liability to the Company; (iii)&nbsp;for each Plan that is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail,
to satisfy the minimum funding standards (within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;to the knowledge of the Company, no Plan is, or is reasonably expected to be, in &#147;at
risk status&#148; (within the meaning of Section&nbsp;303(i) of ERISA) and no Plan that is a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#147;endangered status&#148; or &#147;critical status&#148;
(within the meaning of Sections 304 and 305 of ERISA)&nbsp;(v) the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no
&#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c) of ERISA and the regulations promulgated thereunder) has occurred or, to the knowledge of the Company, is reasonably expected to occur that either has resulted, or would
reasonably be expected to result, in material liability to the Company; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure to act,
which would cause the loss of such qualification; (viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or
premiums to the Pension Benefit Guaranty Corporation, in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and (ix)&nbsp;none of the
following events has occurred or is reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of
the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#146;s and its Controlled Group affiliates&#146; most recently completed fiscal year; or (B)&nbsp;a material increase in the Company and
its subsidiaries&#146; &#147;accumulated post-retirement benefit obligations&#148; (within the meaning of Accounting Standards Codification Topic <FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such obligations in the
Company and its subsidiaries&#146; most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse
Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>Disclosure Controls</I>. The Company and its subsidiaries maintain an effective system of &#147;disclosure
controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of the Exchange Act applicable to the Company and that has been designed to ensure that
information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including
controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. The Company has carried out an evaluation of
the effectiveness of its disclosure controls and procedures to the extent required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>Accounting Controls.</I> The Company and its subsidiaries maintain
systems of &#147;internal control over financial reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that have been designed to comply with the requirements of the Exchange Act applicable to the
Company and have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are
executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability;
(iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate
action is taken with respect to any differences; and (v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package fairly
presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. Based on the Company&#146;s most recent evaluation of its internal controls over financial
reporting pursuant to Rule <FONT STYLE="white-space:nowrap">13a-15(c)</FONT> of the Exchange Act, except, as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses in the
Company&#146;s internal controls. The Company&#146;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses, if any, in the design or operation of
internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and (ii)&nbsp;to the knowledge of the
Company, any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#146;s internal controls over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>eXtensible Business Reporting Language.</I> The interactive data in eXtensible Business Reporting Language included or
incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <I>Insurance. </I>The Company and its subsidiaries have insurance covering their respective properties, operations,
personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks which the Company reasonably believes are adequate to protect the Company and its subsidiaries and their
respective businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to
continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary
to continue its business. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>Cybersecurity; </I>Except as disclosed in the Registration
Statement, the Prospectus and the Time of Sale Information, (i)(x) there has been no security breach or other compromise of or relating to any of the Company&#146;s information technology and computer systems, networks, hardware, software, data
(including the data of its customers, employees, suppliers, vendors and any third party data maintained by or on behalf of the Company), equipment or technology (collectively, &#147;<B>IT Systems and Data</B>&#148;) and (y) the Company has not been
notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii)&nbsp;the Company is presently in compliance with all applicable laws
or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the
protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, in the case of clause (i)&nbsp;and (ii), individually or in the aggregate, have a Material Adverse Effect; and
(iii)&nbsp;the Company has implemented backup and disaster recovery technology consistent with industry standards and practices. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>No Unlawful Payments.</I> Neither the Company nor any of its subsidiaries, nor any director, officer or employee of the
Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;used any corporate funds for any unlawful
contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or
domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party
or party official or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating
Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, agreed,
requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any unlawful rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and its
subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Compliance with Anti-Money Laundering Laws</I>. The operations of
the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or
enforced by any governmental agency (collectively, the &#147;<B>Anti-Money Laundering Laws</B>&#148;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any
of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries, directors, officers or
employees, nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or enforced by
the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;<B>OFAC</B>&#148;) or the U.S. Department of State and including, without limitation, the designation as a
&#147;specially designated national&#148; or &#147;blocked person&#148;), the United Nations Security Council (&#147;<B>UNSC</B>&#148;), the European Union, His Majesty&#146;s Treasury (&#147;<B>HMT</B>&#148;) or other relevant sanctions authority
(collectively, &#147;<B>Sanctions</B>&#148;), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, the <FONT
STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">non-Ukrainian</FONT> government controlled areas
of the Zaporizhzhia and Kherson regions of Ukraine, and any other Covered Region of Ukraine identified pursuant to Executive Order 14065, the Crimea region of Ukraine, Cuba, Iran, North Korea and Syria (each, a &#147;<B>Sanctioned
Country</B>&#148;); and the Company will not directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person
or entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any
Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. Since the Company&#146;s
inception, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of
Sanctions or with any Sanctioned Country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <I>No Restrictions on Subsidiaries</I>. No subsidiary of the Company is
currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock or
similar ownership interest, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s properties or assets to the Company or any other subsidiary of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>No Broker&#146;s Fees.</I> Neither the Company nor any of its
subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder&#146;s fee or like
payment in connection with the offering and sale of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>No Registration Rights</I>. Except as
disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the
filing of the Registration Statement with the Commission, the issuance and sale of the Securities, other than rights that have been validly waived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <I>No Stabilization.</I> Neither the Company nor any of its subsidiaries or affiliates has taken, directly or indirectly,
any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <I>Margin Rules</I>. Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof
by the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of
Governors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <I>Forward-Looking Statements.</I> No forward-looking statement (within the meaning of Section&nbsp;27A of
the Securities Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has
been disclosed other than in good faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <I>Statistical and Market Data.</I> Nothing has come to the attention of the
Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived
from sources that are reliable and accurate in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <I>Sarbanes-Oxley Act</I>. There is and has
been no failure on the part of the Company or, to the Company&#146;s knowledge, any of the Company&#146;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and
the rules and regulations promulgated in connection therewith (the &#147;<B>Sarbanes-Oxley Act</B>&#148;), including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <I>Status under the Securities Act</I>. At the time of filing the
Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the
Securities and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) under the
Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <I>No Ratings</I>. There are (and prior to the Closing Date, will be) no debt securities, convertible securities or
preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a &#147;nationally recognized statistical rating organization&#148;, as such term is defined in Section&nbsp;3(a)(62) under the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <I>Preclinical Studies and Clinical Trials</I>. (i)&nbsp;Except as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, the preclinical studies and clinical trials conducted by or, to the knowledge of the Company, on behalf of or sponsored by the Company or its subsidiaries, or in which the Company or its subsidiaries have
participated, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as
applicable, were, and if still pending are, being conducted in all material respects in accordance with standard medical and scientific research standards and procedures for products or product candidates comparable to those being developed by the
Company and all applicable statutes and all applicable rules and regulations of the U.S. Food and Drug Administration and comparable regulatory agencies outside of the United States to which they are subject, including the European Medicines Agency
(collectively, the &#147;<B>Regulatory Authorities</B>&#148;) and Good Clinical Practice and Good Laboratory Practice requirements; (ii)&nbsp;the descriptions in the Registration Statement, the Pricing Disclosure Package and the Prospectus of the
results of such studies and trials are accurate and complete descriptions in all material respects and fairly present the data derived therefrom; (iii)&nbsp;the Company has no knowledge of any other studies or trials not described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, the results of which are inconsistent with or call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the
Prospectus; (iv)&nbsp;the Company and its subsidiaries have operated at all times and are currently in compliance with all applicable statutes, rules and regulations of the Regulatory Authorities, except that where such <FONT
STYLE="white-space:nowrap">non-compliance</FONT> would not, individually or in the aggregate, have a Material Adverse Effect; (v)&nbsp;the Company has provided the Underwriters with all substantive written notices, correspondence and summaries of
all other communications from the Regulatory Authorities; and (vi)&nbsp;neither the Company nor any of its subsidiaries have received any written notices, correspondence or other communications from the Regulatory Authorities or any other
governmental agency requiring or threatening the termination, material modification or suspension of any preclinical studies or clinical trials that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or
the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, other than ordinary course communications with respect to modifications in connection with the design and implementation of such
studies or trials, and, to the Company&#146;s knowledge, there are no reasonable grounds for the same. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <I>Regulatory Filings</I>. The Company has not failed to file with the
Regulatory Authorities any required filing, declaration, listing, registration, report or submission with respect to the Company&#146;s product candidates that are described or referred to in the Registration Statement, the Pricing Disclosure
Package and the Prospectus; all such filings, declarations, listings, registrations, reports or submissions, as applicable, were in material compliance with applicable laws when filed; and no material deficiencies regarding compliance with
applicable law have been asserted by any applicable regulatory authority with respect to any such filings, declarations, listings, registrations, reports or submissions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Agreements of the Company</U>. The Company covenants and agrees with each Underwriter that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Required Filings.</I> The Company will file the final Prospectus with the Commission within the time periods specified
by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will file promptly all reports and any definitive proxy or
information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is
required in connection with the offering or sale of the Securities; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to
10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Delivery of Copies.</I> Upon the written request of the Representatives, the Company will deliver, without charge,
(i)&nbsp;to the Representatives two conformed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and
(ii)&nbsp;to each Underwriter (A)&nbsp;a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the
Prospectus (including all amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term &#147;Prospectus Delivery
Period&#148; means such period of time after the first date of the public offering of the Securities as in the opinion of counsel for the Underwriters a prospectus relating to the Securities] is required by law to be delivered (or required to be
delivered but for Rule 172 under the Securities Act) in connection with sales of the Securities by any Underwriter or dealer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Amendments or Supplements, Issuer Free Writing Prospectuses.</I>
Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, before filing any amendment to the Registration Statement during the Prospectus Delivery Period or any supplement to the Registration
Statement relating to the offering of the Securities, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, whether before or after the time the Registration Statement becomes
effective, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or
file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably object in a timely manner. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Notice to the Representatives.</I> During the Prospectus Delivery Period, the Company will advise the Representatives
promptly, and confirm such advice in writing (which may be by electronic mail), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective; (iii)&nbsp;when
any supplement to the Pricing Disclosure Package, Prospectus, any Issuer Free Writing Prospectus or any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the Registration
Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information; (v)&nbsp;of the issuance by
the Commission or any other governmental or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the
Prospectus or the initiation or threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which
the Prospectus, any of the Pricing Disclosure Package, any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading; and (vii)&nbsp;of the receipt by the Company of
any notice with respect to any suspension of the qualification of the Securities for offer and sale in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any proceeding for such purpose; and the Company will use
its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus
or suspending any such qualification of the Securities and, if any such order is issued, will use its reasonable best efforts to obtain as soon as possible the withdrawal thereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Ongoing Compliance.</I> (1)&nbsp;If during the Prospectus Delivery
Period (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company will
as promptly as practicable notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such
amendments or supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be
filed with the Commission and incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if at
any time prior to the Closing Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or
supplement the Pricing Disclosure Package to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to
the Underwriters and to such dealers as the Representatives may designate, such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary
so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing
Disclosure Package will comply with law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Blue Sky Compliance.</I> If required by applicable law, the Company will
qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of the
Securities; <I>provided</I> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify,
(ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Earning Statement. </I>The Company will make generally available to its security holders and the Representatives as soon
as reasonably practicable an earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first
fiscal quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement; <I>provided</I> that the Company will be deemed to have furnished such statements to its security holders and the
Representatives to the extent they are filed on the Commission&#146;s Electronic Data Gathering, Analysis, and Retrieval system (&#147;<B>EDGAR</B>&#148;) or any successor system. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Clear Market.</I> For a period of 60 days after the date of the
Prospectus, the Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose
of, directly or indirectly, or file with or confidentially submit to, or file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable
for Stock, or publicly disclose the intention to make any offer, sale, pledge, disposition, submission or filing, or otherwise undertake any of the foregoing, or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part,
any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise,
without the prior written consent of the Representatives other than (A)&nbsp;the Securities to be sold hereunder, (B)&nbsp;any shares of Stock of the Company issued upon the exercise of options or vesting of restricted stock units granted under
Company Stock Plans, (C)&nbsp;upon exercise of any warrant or option or the conversion of the units of the Company outstanding as of the date of this Agreement, (D)&nbsp;up to 5% of the Company&#146;s outstanding securities (as determined
immediately following the issuance and sale of the Shares) issued by the Company in connection with mergers, acquisitions, licenses or commercial collaboration or strategic transactions, (E)&nbsp;filing by the Company of resale registration
statements on Form <FONT STYLE="white-space:nowrap">S-3</FONT> relating to shares of Stock of the Company issued or issuable in connection with mergers, acquisitions, licenses or commercial collaboration or strategic transactions, (F)&nbsp;the
filing by the Company of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto relating to a Company Stock Plan described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, (G)&nbsp;sales of Stock under the Company&#146;s &#147;at the market&#148; program pursuant to the amended and restated sales agreement, by and between the Company and Jefferies LLC, dated March&nbsp;13, 2024, <I>provided</I> that no
sales pursuant to this clause (G)&nbsp;shall be made until 30 days from the date of the Prospectus, or (H)&nbsp;the delivery of Warrant Shares upon exercise of the Warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Use of Proceeds.</I> The Company will apply the net proceeds from the sale of the Securities as described in each of the
Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Stabilization.</I> Neither the Company nor its subsidiaries or affiliates will take, directly or indirectly, any
action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange Listing.</I> The Company will use its reasonable best efforts to list, subject to notice of issuance, the
Shares and the Warrant Shares on the Nasdaq Global Select Market. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Reports.</I> For a period of three years from the date of this
Agreement, the Company, so long as the Securities or the Warrant Shares are outstanding, will furnish to the Representatives, as soon as commercially reasonable after the date they are available, copies of all reports or other communications
(financial or other) furnished to holders of the Securities or the Warrant Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system;
<I>provided</I> that the Company will be deemed to have furnished such reports and financial statements to the Representatives to the extent they are filed on EDGAR, or any successor to such system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each
Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Shelf Renewal</I>. If immediately prior to the third anniversary (the &#147;<B>Renewal Deadline</B>&#148;) of the
initial effective date of the Registration Statement, any of the Securities remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a new automatic shelf
registration statement relating to the Securities, in a form satisfactory to the Representatives. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has not
already done so, file a new shelf registration statement relating to the Shares, in a form satisfactory to the Representatives, and will use its best efforts to cause such registration statement to be declared effective within 180 days after the
Renewal Deadline. The Company will take all other action necessary or appropriate to permit the issuance and sale of the Securities to continue as contemplated in the expired registration statement relating to the Securities. References herein to
the Registration Statement shall include such new automatic shelf registration statement or such new shelf registration statement, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Warrant Shares Reserved. </I>The Company shall, at all times while any Warrants are outstanding, reserve and keep
available out of its authorized but unissued and otherwise unreserved shares of common stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of such Warrants, the number of Warrant Shares that are initially issuable and
deliverable upon the exercise of the then-outstanding Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain Agreements of the Underwriters</U>. Each Underwriter hereby
represents and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has not and will not use, authorize use of, refer to or participate in the planning for
use of, any &#147;free writing prospectus&#148;, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration
Statement and any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through
incorporation by reference) in </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on <U>Annex A</U> or prepared pursuant to Section&nbsp;3(c) or
Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such Underwriter and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses
(i)&nbsp;or (iii), an &#147;<B>Underwriter Free Writing Prospectus</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It has not, and will not, without the
prior written consent of the Company, use any free writing prospectus that contains the final terms of the Securities unless such terms have previously been included in a free writing prospectus filed with the Commission; <I>provided</I> that the
Underwriters may use a term sheet substantially in the form of <U>Annex B</U> hereto without the consent of the Company; <I>provided</I>, <I>further</I>, that any Underwriter using such term sheet shall notify the Company, and provide a copy of such
term sheet to the Company, prior to, or substantially concurrently with, the first use of such term sheet. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It is not
subject to any pending proceeding under Section&nbsp;8A of the Securities Act with respect to the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase the Securities on the Closing Date as
provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be
in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with
the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission for
additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Representations and Warranties.</I> The representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date; and the statements of the Company and its officers made in any
certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No
Material Adverse Change.</I> No event or condition of a type described in Section&nbsp;3(h) hereof shall have occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement
thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the
Closing Date, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Officer&#146;s Certificate.</I> The Representatives shall have
received on and as of the Closing Date a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Representatives on behalf of the
Company and not in their individual capacities (i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations
set forth in Sections 3(b) and 3(d) hereof are true and correct in all material respects except as already so qualified, (ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement are true and correct in all
material respects except as already so qualified and that the Company has complied with all agreements in all material respects and satisfied all conditions in all material respects on its part to be performed or satisfied hereunder at or prior to
the Closing Date and (iii)&nbsp;to the effect set forth in paragraphs (a), (b) and (c)&nbsp;above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Comfort
Letters.</I> On the date of this Agreement and on the Closing Date PricewaterhouseCoopers LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the
Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters, delivered according to
Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to the financial statements and certain financial information contained in or incorporated by reference in each of the Registration Statement, the Pricing
Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Chief Financial Officer&#146;s Certificate</I>. On the date of this
Agreement and on the Closing Date the Company shall have furnished to the Representatives a certificate, dated the respective dates of delivery thereof and addressed to the Underwriters, of its chief financial officer with respect to certain
financial data contained in the Pricing Disclosure Package and the Prospectus and any Issuer Free Writing Prospectus, as applicable, providing &#147;management comfort&#148; with respect to such information, in form and substance reasonably
satisfactory to the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel
for the Company.</I> Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion substantially in form and substance reasonably satisfactory to
the Representatives, dated the Closing Date and their <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated the Closing Date and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Opinions of Intellectual Property Counsel for the Company.</I> Knobbe, Martens, Olson&nbsp;&amp; Bear, LLP and
McCarter&nbsp;&amp; English LLP, each intellectual property counsel for the Company, shall have furnished to the Representatives, their respective written opinions, each dated the Closing Date and addressed to the Underwriters, substantially in form
and substance reasonably satisfactory to the Representatives. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement
of Counsel for the Underwriters.</I> The Representatives shall have received on and as of the Closing Date an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, addressed to the Underwriters, of Davis Polk&nbsp;&amp; Wardwell LLP,
counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Legal Impediment to Issuance and Sale.</I> No action shall have been taken and no statute, rule, regulation or
order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date prevent the issuance or sale of the Securities; and no injunction or order of any federal,
state or foreign court shall have been issued that would, as of the Closing Date prevent the issuance or sale of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Good Standing</I>. The Representatives shall have received on and as of the Closing Date satisfactory evidence of the
good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing in such other jurisdictions as the Representatives may reasonably request, in each case in writing or any standard form of
telecommunication from the appropriate governmental authorities of such jurisdictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Exchange Listing.</I> A
Listing of Additional Shares related to the Shares to be delivered on the Closing Date and any Warrant Shares to be delivered upon exercise of the Warrants shall have been filed on the Nasdaq Global Select Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of <U>Exhibit A</U> hereto, between you and the individuals and entities listed on <U>Exhibit B</U> hereto relating to sales and certain other
dispositions of shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Additional Documents.</I> On or prior to the Closing Date the Company shall have furnished to the Representatives such
further certificates and documents as the Representatives may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Form of Warrant</I>. On or prior
to the Closing Date, the Representatives shall have received a form of Warrant in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the
provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Underwriters.</I> The Company agrees to indemnify and hold harmless each Underwriter, its affiliates that are
broker dealers and selling Securities on behalf of the Underwriters, its directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange
Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, reasonable legal fees and other reasonable expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such
fees and expenses are incurred), joint or several, that arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged
omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the
Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any road show as
defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein
a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon,
any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives
expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in paragraph (b)&nbsp;below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company.</I> Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its
directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity
set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in
conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement
thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the
only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the fifth paragraph under the caption
&#147;Underwriting&#148;, the information contained in the twelfth paragraph relating to stabilizing transactions under the caption &#147;Underwriting.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice and Procedures.</I> If any suit, action, proceeding (including any
governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;7, such person (the
&#147;<B>Indemnified Person</B>&#148;) shall promptly notify the person against whom such indemnification may be sought (the &#147;<B>Indemnifying Person</B>&#148;) in writing; <I>provided</I> that the failure to notify the Indemnifying Person shall
not relieve it from any liability that it may have under the preceding paragraphs of this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and
<I>provided</I>, <I>further</I>, that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any such
proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without
the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section&nbsp;7 that the Indemnifying Person may designate in such
proceeding and shall pay the reasonable fees and documented expenses in such proceeding and shall pay the reasonable and documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified
Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the
contrary; (ii)&nbsp;the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses
available to it that are different from or in addition to those available to the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified
Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding
or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as
they are incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such
Underwriter shall be designated in writing by the Representatives and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the Company shall be designated in writing by
the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and
against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for reasonable and documented
fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 60 days after
receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the
written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such
Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of
such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;and (b)
above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person
thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company,
on the one hand, and the Underwriters, on the other, from the offering of the Securities or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the
relative benefits referred to in clause (i)&nbsp;but also the relative fault of the Company, on the one hand, and the Underwriters, on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or
liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other, shall be deemed to be in the same respective proportions as the net proceeds
(before deducting expenses) received by the Company from the sale of the Securities and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the
Prospectus, bear to the aggregate offering price of the Securities. The relative fault of the Company, on the one hand, and the Underwriters, on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters, and the parties&#146; relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company and the Underwriters agree that it
would not be just and equitable if contribution pursuant to paragraph (d)&nbsp;above were determined by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does
not take account of the equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be
deemed to include, subject to the limitations set forth above, any reasonable and documented legal or other reasonable and documented expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the
provisions of paragraph (d), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the
Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the
meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to paragraph (d)&nbsp;above are
several in proportion to their respective purchase obligations hereunder and not joint. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The remedies
provided for in this Section&nbsp;7 paragraphs (a)&nbsp;through (e) are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date first written above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after
the execution and delivery of this Agreement and on or prior to the Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on or by either the New York Stock Exchange or The Nasdaq Stock Market; (ii)&nbsp;trading of
any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on
commercial banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either
within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date on the terms
and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Defaulting Underwriter</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If, on the Closing Date any Underwriter defaults on its obligation to purchase the Securities that it has agreed to purchase
hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Securities by other persons satisfactory to the Company on the terms contained in this
Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Securities, then the Company shall be entitled to a further
period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Securities on such terms. If other persons become obligated or agree to purchase the
Securities of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date for up to five full business days in order to effect any changes that in the opinion
of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the
Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in
<U>Schedule 1</U> hereto that, pursuant to this Section&nbsp;10, purchases Securities that a defaulting Underwriter agreed but failed to purchase. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Securities of a
defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Securities that remain unpurchased on the Closing Date
does not exceed <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate number of Securities to be purchased on such date, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriter to purchase the number of Securities that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Securities that such Underwriter agreed to purchase on such date) of
the Securities of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect
to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate
number of Securities that remain unpurchased on the Closing Date exceeds <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate amount of Securities to be purchased on such date, or if the Company shall not exercise the right described
in paragraph (b)&nbsp;above, then this Agreement shall terminate without liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be
without liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall
remain in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Payment of Expenses</U><I>. </I>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay
or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including, without limitation (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Securities to the
Underwriters and any taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, any Preliminary Prospectus, any Issuer Free Writing Prospectus, any
Pricing Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants; (iv)&nbsp;the fees
and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Securities under the laws of such jurisdictions as the Representatives may designate and the preparation, printing and
distribution of a Blue Sky Memorandum (including the related reasonable fees and expenses of counsel for the Underwriters);&nbsp;(v) the cost of preparing stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any registrar;
(vii)&nbsp;all expenses and application fees incurred in connection with any filing with, and clearance of the offering by, FINRA, <I>provided</I> that the amount payable by the Company pursuant to clauses (iv)&nbsp;and (vii) shall not exceed
$35,000; (viii) all expenses incurred by the Company in connection with any &#147;road show&#148; presentation to potential investors and (ix)&nbsp;all expenses and application fees related to the listing of the Shares and the Warrant Shares on the
Nasdaq Global Select Market. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9, (ii) the Company
for any reason fails to tender the Securities for delivery to the Underwriters (other than by reason of a default by any Underwriter) or (iii)&nbsp;the Underwriters decline to purchase the Securities for any reason permitted under this Agreement,
the Company agrees to reimburse the Underwriters for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the
Underwriters in connection with this Agreement and the offering contemplated hereby. For avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by an Underwriter pursuant to this
paragraph (b)&nbsp;that defaults on its obligations to purchase the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Persons Entitled to Benefit of Agreement</U>. This
Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein and the affiliates of each Underwriter referred to in
Section&nbsp;7 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of
Securities from any Underwriter shall be deemed to be a successor merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Survival</U>. The respective
indemnities, rights of contribution, representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate
delivered pursuant hereto shall survive the delivery of and payment for the Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the
Underwriters or the directors, officers, controlling persons or affiliates referred to in Section&nbsp;7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined
Terms</U>. For purposes of this Agreement, (a)&nbsp;except where otherwise expressly provided, the term &#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day
other than a day on which banks are permitted or required to be closed in New York City; and (c)&nbsp;the term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT
STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include
the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be
given to the Representatives c/o Jefferies LLC, 520 Madison Avenue, New York, New York 10022, Attention: General Counsel; c/o Leerink Partners LLC, 1301 Avenue of the Americas, 5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, New
York, New York 10019, Attention: Stuart R. Nayman, Esq., Email: stuart.nayman@leerink.com. Notices to the Company shall be given to it at 500 Rutherford Avenue, 3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> Floor, Charlestown,
Massachusetts 02129, Attention: General Counsel, email: [***]. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Governing Law.</I> This Agreement and any claim, controversy or dispute arising under
or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Submission
to Jurisdiction. </I>The Company hereby submits to the exclusive jurisdiction of the U.S. federal and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or
the transactions contemplated hereby. The Company waives any objection which it may now or hereafter have to the laying of venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or
proceeding brought in such court shall be conclusive and binding upon the Company and may be enforced in any court to the jurisdiction of which Company is subject by a suit upon such judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Waiver of Jury Trial.</I> EACH OF THE PARTIES HERETO HEREBY WAIVES ANY RIGHT TO TRIAL BY JURY IN ANY SUIT OF PROCEEDING ARISING OUT OF
OR RELATING TO THIS AGREEMENT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Recognition of the U.S. Special Resolution Regimes</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As used in
this Section&nbsp;16(e): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance
with, 12 C.F.R. &#167; 382.2(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in
accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of
(i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Counterparts.</I> This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of
telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. The words &#147;execution,&#148; &#147;signed,&#148; &#147;signature,&#148; and words of like import in this Agreement or
in any other certificate, agreement or document related to this Agreement or the offering and sale of the Securities shall include images of manually executed signatures transmitted by facsimile or other electronic format (including, without
limitation, &#147;pdf&#148;, &#147;tif&#148; or &#147;jpg&#148;) and other electronic signatures (including, without limitation, DocuSign and AdobeSign). The use of electronic signatures and electronic records (including, without limitation, any
contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping system
to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable law, including, without limitation,
any state law based on the Uniform Electronic Transactions Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Amendments or Waivers.</I> No amendment or waiver of any provision
of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the
meaning or interpretation of, this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">SOLID BIOSCIENCES INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Kevin Tan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Kevin Tan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted: As of the date first written above </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LEERINK PARTNERS LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For themselves and on behalf of the</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">several Underwriters listed</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">in <U>Schedule 1</U> hereto.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC</P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Matthew Kim</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Matthew Kim</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Joint US Head of Biopharmaceuticals</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">LEERINK PARTNERS LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Sean Pitt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Sean Pitt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Senior Managing Director</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>Warrants</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,976,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,596,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,189,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,902,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Blair&nbsp;&amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,680,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,041,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">893,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">347,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>35,739,810</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,888,340</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch. 1-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>a. Pricing Disclosure Package </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The free
writing prospectus dated as of February&nbsp;18, 2025 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>b. Pricing Information Provided Orally by Underwriters </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares: 35,739,810 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Public Offering Price Per Share: $4.03 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Warrants: 13,888,340 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Public Offering Price Per Warrant: $4.029 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares and warrants to be issued may be reallocated among shares or warrants such that the
aggregate number of shares and warrants issued does not exceed 49,628,150. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exercise Price for the Warrants: $0.001 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex A </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">February [&#149;], 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters listed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in <U>Schedule 1</U> hereto </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 State Street, 40<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02109 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re:&#8195;SOLID
BIOSCIENCES INC. &#151;- Public Offering </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that you, as Representatives of the several Underwriters, propose to enter into an underwriting agreement (the
&#147;Underwriting Agreement&#148;) with Solid Biosciences Inc., a Delaware corporation (the &#147;Company&#148;), providing for the public offering (the &#147;Public Offering&#148;) by the several Underwriters named in <U>Schedule 1</U> to the
Underwriting Agreement (the &#147;Underwriters&#148;), of shares of common stock, par value $0.001 per share (the &#147;Common Stock&#148;), of the Company and, if applicable, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase
shares of Common Stock (the &#147;Securities&#148;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Underwriters&#146; agreement to purchase and make the Public Offering of the Securities, and for other good and
valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of Jefferies LLC and Leerink Partners LLC on behalf of the Underwriters, the undersigned will not, and will not
cause any direct or indirect affiliate to, during the period beginning on the date of this letter agreement (this &#147;Letter Agreement&#148;) and ending 60 days after the date of the prospectus relating to the Public Offering (the
&#147;Prospectus&#148;) (such period, the &#147;Restricted Period&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase,
lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convertible into or exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the
undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) (collectively with the Common Stock,
<FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Securities&#148;), or publicly disclose the intention to make any offer, sale, pledge or disposition, (2)&nbsp;enter into any hedging, swap or other agreement or transaction that transfers, in
whole or in part, any of the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or otherwise or (3)&nbsp;make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or
exchangeable for Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing paragraph shall not apply to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) transactions relating to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities that the undersigned may purchase in the Public
Offering or in open market transactions during the Restricted Period, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) the exercise, including by &#147;net&#148; or
&#147;cashless&#148; exercise, so long as exercised in accordance with clauses (C)&nbsp;and (D) below, of any options or warrants to acquire shares of Common Stock or the conversion of any convertible security into Common Stock described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, or issued pursuant to an equity plan described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, it being understood that any shares of Common
Stock received shall be subject to the restrictions on transfer set forth in this Letter Agreement, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) the sale or transfer to the
Company of such number of shares of Common Stock acquired by the undersigned in connection with the exercise of such options or warrants on a &#147;net&#148; or &#147;cashless&#148; exercise basis described in the foregoing clause, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) the sale or transfer to the Company of such number of shares of Common Stock necessary to generate only such amount of cash needed for the
payment of taxes (including estimated taxes) due as a result of the exercise of such options or warrants or the conversion of any convertible security described in clause (C), </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) the transfer, sale or other disposition of shares of Common Stock in connection with the vesting or settlement of restricted stock units
in an amount sufficient to cover withholding taxes due in connection with such vesting or settlement of restricted stock units, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(F)&nbsp;transfers of shares of Common Stock as a bona fide gift or gifts or pursuant to a negotiated divorce settlement, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(G) transfers pursuant to a qualified domestic relations order, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(H)&nbsp;distributions or transfers of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities to subsidiaries, limited or general
partners, members, stockholders or affiliates of, or any investment fund or other entity that controls or manages, the undersigned, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(I) transfers of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities to any immediate
family member, trusts for the direct or indirect benefit of the undersigned or the immediate family members of the undersigned or any of their successors upon death, or any partnerships or limited liability company, the partners or members of which
consist of or are for the direct or indirect benefit of the undersigned and/or immediate family members or other dependents of the undersigned, (for purposes of this Letter Agreement, &#147;immediate family&#148; means any relationship by blood,
marriage or adoption, not more remote than first cousin), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(J) transfers of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities of
the Company by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the undersigned in a transaction not involving a disposition for value, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(K) any forfeiture, sale or other transfer to the Company of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities in connection with
the termination of the undersigned&#146;s employment with or services to the Company, <U>provided</U> that no public announcement reporting a reduction in the beneficial ownership shall be voluntarily made, and any required announcement, including
any announcement under the Securities Exchange Act of 1934, as amended, shall clearly indicate the reason for such reduction, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(L)
transactions pursuant to a contract, instruction or plan meeting the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act (a <FONT STYLE="white-space:nowrap">&#147;10b5-1</FONT> Plan&#148;); provided that such <FONT
STYLE="white-space:nowrap">10b5-1</FONT> Plan was established prior to the execution of this agreement by the undersigned, the existence and details of such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan were communicated to the Representatives
and such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan will not be amended or otherwise modified during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>provided</U> that in the case of any transfer or distribution pursuant to clauses (F), (G), (H), (I) and (J), each donee, distributee or
transferee shall execute and deliver to Jefferies LLC and Leerink Partners LLC, a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this paragraph; and <U>provided</U>, <U>further</U>, that in the case of any transfer or
distribution pursuant to clauses (A)&nbsp;through (F) and (H)&nbsp;through (J), no filing by any party (donor, donee, transferor or transferee) under the Securities Exchange Act of 1934, as amended, or other public announcement reporting a reduction
in the beneficial ownership shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a required filing on Form 144 and Form 4 that clearly indicates the reason for such reduction and a filing on a
Form 5 or 13F filing made after the expiration of the Restricted Period and any required Schedule 13G (or 13G/A)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the
foregoing paragraph shall not apply to the establishment of a trading plan by the undersigned pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of Common Stock, provided that such plan
does not provide for the transfer of Common Stock during the Restricted Period and, no public announcement or filing under the Exchange Act, if any, is required of or is voluntarily made by or on behalf of the undersigned or the Company regarding
such plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions contained herein shall not apply to any transfers, sales, tenders or other
dispositions of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock pursuant to a bona fide third-party tender offer, merger, amalgamation, consolidation or other similar transaction made to or involving all
holders of the Common Stock or such other securities pursuant to a change of control of the ownership of the Company (including, without limitation, the entry into any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement
pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Common Stock or other such securities in favor of any such transaction); <U>provided </U>that if such tender offer, merger, amalgamation, consolidation or
other similar transaction is not completed, any Common Stock or any security convertible into or exercisable or exchangeable for Common Stock subject to this Letter Agreement shall remain subject to the restrictions contained in this Letter
Agreement. For purposes of this Letter Agreement, &#147;change of control&#148; shall mean the consummation of any bona fide third party tender offer, merger, amalgamation, consolidation or other similar transaction the result of which is that any
&#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, other than the Company, becomes the beneficial owner (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT
STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of 50% of total voting power of the voting stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would
constitute a violation or breach of this Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full
power and authority to enter into this Letter Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the
undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor
have the Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed
appropriate. The undersigned further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Public Offering, the
Representatives and the other Underwriters are not making a recommendation to you to enter into this Letter Agreement, and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a
recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if (A)&nbsp;either the Company, on the one hand, or Jefferies LLC and Leerink Partners
LLC on behalf of the Underwriters, on the other hand, notifies the other in writing, prior to the execution of the Underwriting Agreement, that they have determined not to proceed with the Public Offering, (B)&nbsp;the Underwriting Agreement does
not become effective by March&nbsp;31, 2025, (C)&nbsp;the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities to be sold thereunder
or (D)&nbsp;the Registration Statement is withdrawn, prior to the execution of the Underwriting Agreement, the undersigned shall be released from all obligations under this Letter Agreement. The undersigned understands that the Underwriters are
entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this
Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[NAME OF STOCKHOLDER]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">LOCK-UP</FONT> PARTIES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#149;] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Form of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to be circulated separately</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d908068dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SOLID BIOSCIENCES INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">&#8195;&nbsp;Number of Shares: [&#8195;&#8195;&#8195;&#8195;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(subject to adjustment) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant No. <U>&#8195;</U><U></U><U></U><U></U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Original&nbsp;Issue&nbsp;Date:&nbsp;February [&#8195;], 2025</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solid Biosciences Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that, for good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, [&#8195;] or its registered assigns (the &#147;<B>Holder</B>&#148;), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of
[&#8195;] shares of common stock, $0.001<B> </B>par value per share (the &#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the &#147;<B>Warrant Shares</B>&#148;) at an exercise
price per share equal to $0.001 per share (as adjusted from time to time as provided in <U>Section</U><U></U><U>&nbsp;9</U> herein, the &#147;<B>Exercise Price</B>&#148;), upon surrender of this Warrant to Purchase Common Stock (including any
Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to time on or after the date hereof (the &#147;<B>Original Issue Date</B>&#148;) and through and
including the date this Warrant is exercised in full (the &#147;<B>Expiration Date</B>&#148;), subject to the following terms and conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.
<I>Definitions</I>. For purposes of this Warrant, the following terms shall have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Affiliate</B>&#148;
means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, but only for so long as such control shall continue. For purposes of this definition, &#147;control&#148; (including, with correlative
meanings, &#147;controlled by&#148;, &#147;controlling&#148; and &#147;under common control with&#148;) means, with respect to a Person, possession, direct or indirect, of (i)&nbsp;the power to direct or cause direction of the management and
policies of such Person (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (ii)&nbsp;at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other
similar arrangement) or other comparable equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Attribution Parties</B>&#148; means, collectively, the following
Persons and entities: (i)&nbsp;any direct or indirect Affiliates of the Holder, (ii)&nbsp;any Person acting or who could be deemed to be acting as a Section&nbsp;13(d) &#147;group&#148; together with the Holder or any Attribution Parties and
(iii)&nbsp;any other Persons whose beneficial ownership of the Company&#146;s Common Stock would or could be aggregated with the Holder&#146;s and/or any other Attribution Parties for purposes of Section&nbsp;13(d) or Section&nbsp;16 of the Exchange
Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Closing Sale Price</B>&#148; means, for any security as of any date, the last trade price for such security on the Principal
Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security
prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets. If the Closing Sale Price cannot be calculated for
a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to
agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#146; determination shall be binding upon all parties absent
demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Commission</B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Group</B>&#148; shall have the meaning ascribed to it in Section&nbsp;13(d) of
the Exchange Act, and all related rules, regulations and jurisprudence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Person</B>&#148; means an individual, a limited
liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Principal Trading Market</B>&#148; means the national securities exchange or other trading market on which the Common Stock is
primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
&#147;<B>Registration Statement</B>&#148;<B> </B>means the Company&#146;s Registration Statement on Form S-3, as amended (File No.&nbsp;333-277871), declared effective on May&nbsp;17, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B>Standard Settlement Period</B>&#148; means the standard settlement period, expressed in a number of Trading Days, for the
Principal Trading Market with respect to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as of the Original Issue Date was &#147;T+1.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market is normally open for trading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) &#147;<B>Transfer Agent</B>&#148; means Computershare Trust Company, N.A., the Company&#146;s transfer agent and registrar for the Common
Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <I>Issuance of Securities; Registration of Warrants</I>. The Warrant, as initially issued by the
Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration
Statement or an exchange meeting the requirements of Section&nbsp;3(a)(9) of the Securities Act as in effect on the Original Issue Date, the Warrant Shares, are not &#147;restricted securities&#148; under Rule 144 promulgated under the Securities
Act.<B> </B>The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the record Holder (which shall include the initial Holder or,
as the case may be, any assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <I>Registration of Transfers</I>. Subject to
compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, together with a written
assignment of this Warrant substantially in the form attached hereto as Schedule 2 duly executed by the Holder, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in
substantially the form of this Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this
Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New
Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s own expense any New Warrant under this <U>Section</U><U></U><U>&nbsp;3</U>. Until due
presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <I>Exercise of Warrants</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All or any
part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant (including Section&nbsp;11) at any time and from time to time on or after the Original Issue Date, and such rights shall not expire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the Company (i)&nbsp;an exercise notice, in the form attached as <U>Schedule 1</U>
hereto (the &#147;<B>Exercise Notice</B>&#148;), completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a &#147;cashless
exercise&#148; if so indicated in the Exercise Notice pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below), and the date on which the last of such items is delivered to the Company (as determined in accordance with the notice provisions hereof)
is an <B>&#147;Exercise Date</B>.&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the
original </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <I>Delivery of Warrant Shares</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than the number of Trading Days comprising the Standard
Settlement Period following the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock specified by the Holder in the Exercise Notice and to which the Holder is entitled pursuant to such exercise (the
&#147;<B>Exercise Shares</B>&#148;) to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company (&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal At Custodian system, or if the Transfer Agent is then a
participant in the DTC Fast Automated Securities Transfer Program (the &#147;<B>FAST Program</B>&#148;) and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or the resale of such Warrant
Shares by the Holder or (B)&nbsp;the Exercise Shares are eligible for resale by the Holder without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions pursuant to Rule 144 promulgated
under the Securities Act (assuming cashless exercise of this Warrant). If the Transfer Agent is not a member of the FAST Program or if (A)&nbsp;and (B) above are not true, the Transfer Agent will either (i)&nbsp;record the Exercise Shares in the
name of the Holder or its designee on the certificates reflecting the Exercise Shares with an appropriate legend regarding restriction on transferability, which shall be issued and dispatched by overnight courier to the address as specified in the
Exercise Notice, and on the Company&#146;s share register or (ii)&nbsp;issue such Exercise Shares in the name of the Holder or its designee in restricted book-entry form in the Company&#146;s share register. The Holder, or any Person so designated
by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#146;s DTC account, the date of the
book entry positions or the date of delivery of the certificates evidencing such Exercise Shares, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the Company
fails to deliver to the Holder or its designee Exercise Shares in the manner required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> within the Standard Settlement Period following the Exercise Date and the Holder purchases (in an open market
transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;)
but did not receive within the Standard Settlement Period, then the Company shall, within two (2)&nbsp;Trading Days after the Holder&#146;s request and in the Holder&#146;s sole discretion, either (1)&nbsp;pay in cash to the Holder an amount equal
to the Holder&#146;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company&#146;s obligation to issue and deliver such Exercise Shares shall terminate or
(2)&nbsp;promptly honor its obligation to deliver to the Holder or its designee the Exercise Shares pursuant to Section&nbsp;5(a) and pay cash to the Holder in an amount equal to the excess (if any) of (x)&nbsp;Holder&#146;s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> less (y)&nbsp;the product of (A)&nbsp;the number of shares of Common Stock purchased in the <FONT
STYLE="white-space:nowrap">Buy-In,</FONT> times (B)&nbsp;the Closing Sale Price of a share of Common Stock on the Exercise Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To
the extent permitted by law and subject to <U>Section</U><U>&nbsp;5(b)</U>, the Company&#146;s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in
<U>Section</U><U></U><U>&nbsp;11</U> below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against
any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged
violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to
<U>Section</U><U>&nbsp;5(b)</U>, nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief
with respect to the Company&#146;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <I>Charges, Taxes and Expenses</I>. Issuance and delivery of shares of Common Stock upon exercise of this Warrant shall be made without charge to the
Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such shares, all of which taxes and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expenses shall be paid by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the
registration of any Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or
receiving Warrant Shares upon exercise hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss,
theft or destruction (in such case) and, in each case, a customary and reasonable contractual indemnity, if requested by the Company. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such
mutilated Warrant to the Company as a condition precedent to the Company&#146;s obligation to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <I>Reservation of Warrant
Shares</I>. The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling
it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent
purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of <U>Section</U><U></U><U>&nbsp;9</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the
payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be
reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the
Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to
time as set forth in this <U>Section</U><U></U><U>&nbsp;9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time while
this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the
Original Issue Date or as amended, that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into
a smaller number of shares of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock, then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of which
shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause
(i)&nbsp;of this <U>Section</U><U></U><U>&nbsp;9(a)</U> shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date
shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to
this <U>Section</U><U></U><U>&nbsp;9(a)</U> as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii)&nbsp;of this <U>Section</U><U></U><U>&nbsp;9(a)</U> shall become effective immediately after the
effective date of such subdivision or combination. Simultaneously with any adjustment to the Exercise Price pursuant to this Section&nbsp;9(a), the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or
decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such
adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If, on or after the Original Issue Date, the Company shall declare or make any dividend or
other pro rata distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property,
options, evidence of indebtedness or any other assets by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction, but, for the avoidance of doubt, excluding any distribution of
shares of Common Stock subject to <U>Section</U><U></U><U>&nbsp;9(a)</U>, any distribution of Purchase Rights (as defined below) subject to <U>Section</U><U></U><U>&nbsp;9(c)</U> and any Fundamental Transaction (as defined below) subject to
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;9(d))</U> (a &#147;<B>Distribution</B>&#148;) then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the
Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without
limitation, the Maximum Percentage (as defined below)) immediately before the date on which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be
determined for the participation in such Distribution (provided, that to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage,
then the Holder shall not be entitled to participate in such Distribution to such extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and beneficial ownership) to such extent)
and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which
time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such
limitation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Purchase Rights</U>. If at any time on or after the Original Issue Date, the Company grants, issues or sells any
Options, Convertible Securities or rights to purchase stock, warrants, securities or other property, in each case pro rata to the record holders of any class of Common Stock (the &#147;<B>Purchase Rights</B>&#148;), then the Holder will be entitled
to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no
such record is taken, the date as of which the record holders of Common Stock are to be determined for the grant, issuance or sale of such Purchase Rights (provided, that to the extent that the Holder&#146;s right to participate in any such Purchase
Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such extent (and shall not be entitled to beneficial ownership of
such Common Stock as a result of such Purchase Right (and beneficial ownership) to such extent) and such Purchase Right to such extent shall be held in abeyance for the benefit of the Holder until such time or times as its right thereto would not
result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any
subsequent Purchase Right to be held similarly in abeyance) to the same extent as if there had been no such limitation). As used in this Section&nbsp;9(c), (i) &#147;Options&#148; means any rights, warrants or options to subscribe for or purchase
shares of Common Stock or Convertible Securities and (ii) &#147;Convertible Securities&#148; mean any stock or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i)&nbsp;the Company effects any merger or
consolidation of the Company with or into another Person, in which the Company is not the surviving entity or in which the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50%
of the voting power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one or a series of related transactions,
(iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such
other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the voting power of the capital stock of the Company (except for any such transaction in which the
stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any reclassification of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by
<U>Section</U><U></U><U>&nbsp;9(a)</U> above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount
and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then
issuable upon exercise in full of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this Warrant without regard to any limitations on exercise contained herein (the &#147;<B>Alternate Consideration</B>&#148;). The Company shall not effect any Fundamental Transaction in which the
Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides for the simultaneous &#147;cashless exercise&#148; of this
Warrant pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company)
shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph
(d)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All
calculations under this <U>Section</U><U></U><U>&nbsp;9</U> shall be made to the nearest <FONT STYLE="white-space:nowrap">one-tenth</FONT> of one cent or the nearest whole share, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this <U>Section</U><U></U><U>&nbsp;9</U>, the Company at
its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted
Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such
adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company&#146;s transfer agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary,
(ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company,
then the Company shall deliver to the Holder a notice of such transaction at least ten (10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect
to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding,
the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by <U>Section</U><U></U><U>&nbsp;9(d)</U>, other than a Fundamental Transaction under clause
(iii)&nbsp;of <U>Section</U><U></U><U>&nbsp;9(d)</U>, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least thirty (30)&nbsp;days prior to the date such Fundamental Transaction is consummated. Holder agrees to
maintain any information disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;9(g)</U> in confidence until such information is publicly available, and shall comply with applicable law with respect to trading in the Company&#146;s securities
following receipt of any such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <I>Payment of Exercise Price</I>. Notwithstanding anything contained herein to the contrary, the Holder
may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a &#147;cashless exercise&#148;, in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant
to Section&nbsp;3(a)(9) of the Securities Act, as determined as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals
the number of Warrant Shares to be issued to the Holder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which
this Warrant is then being exercised; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price of the shares of Common Stock as of the Trading Day on
the date immediately preceding the Exercise Date; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price then in effect for the applicable Warrant
Shares at the time of such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the
Warrant Shares issued in such a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the Original Issue Date (provided,
that the Commission continues to take the position that such treatment is proper at the time of such exercise). Except as set forth in Section&nbsp;5(b) <FONT STYLE="white-space:nowrap">(Buy-In</FONT> remedy) and Section&nbsp;12 (payment of cash in
lieu of fractional shares), in no event will the exercise of this Warrant be settled in cash. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <I>Limitations on Exercise</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect the exercise of any portion of this Warrant, and
the Holder of the Warrant shall not have the right to exercise any portion of the Warrant, and any such exercise shall be null and void ab initio and treated as if the exercise had not been made, to the extent that immediately prior to or following
such exercise, the Holder, together with the Attribution Parties, beneficially owns or would beneficially own as determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder, in excess of [4.99%/9.99%]
(the &#147;<B>Maximum Percentage</B>&#148;) of the Common Stock that would be issued and outstanding following such exercise. For purposes of calculating beneficial ownership for determining whether the Maximum Percentage is or will be exceeded, the
aggregate number of shares of Common Stock held and/or beneficially owned by the Holder together with the Attribution Parties, shall include the number of shares of Common Stock held and/or beneficially owned by the Holder together with the
Attribution Parties plus the number of shares of Common Stock issuable upon exercise of the relevant Warrant with respect to which the determination is being made but shall exclude the number of shares of Common Stock which would be issuable upon
(i)&nbsp;exercise of the remaining, unexercised Warrant held and/or beneficially owned by the Holder or the Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of the Company
held and/or beneficially owned by such Holder or any Attribution Party (including, without limitation, any convertible notes, convertible stock or warrants) that are subject to a limitation on conversion or exercise analogous to the limitation
contained herein. For purposes of this Section&nbsp;11(a), beneficial ownership of the Holder or the Attribution Parties shall, except as set forth in the immediately preceding sentence, be calculated and determined in accordance with
Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder. For purposes of the Warrant, in determining the number of outstanding shares of Common Stock, a Holder of this Warrant may rely on the number of outstanding shares of
Common Stock as reflected in (1)&nbsp;the Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other
public filing with the Commission, as the case may be, (2)&nbsp;a more recent public announcement by the Company or (3)&nbsp;any other notice by the Company or the Company&#146;s transfer agent setting forth the number of shares of Common Stock
outstanding (such issued and outstanding shares, the &#147;<B>Reported Outstanding Share Number</B>&#148;). For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1)&nbsp;Business Day confirm orally
and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. The Holder shall disclose to the Company the number of shares of Common Stock that it, together with the Attribution Parties holds and/or
beneficially owns and has the right to acquire through the exercise of derivative securities and any limitations on exercise or conversion analogous to the limitation contained herein contemporaneously or immediately prior to submitting an Exercise
Notice for the relevant Warrant. If the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i)&nbsp;notify
the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder&#146;s, together with the Attribution Parties&#146;, beneficial ownership, as determined
pursuant to this Section&nbsp;11(a), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be purchased pursuant to such Exercise Notice (the number of shares by which such purchase is reduced,
the &#147;Reduction Shares&#148;) and (ii)&nbsp;as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. In any case, the number of outstanding shares of Common Stock
shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and the Attribution Parties since the date as of which the Reported Outstanding Share Number was reported. In
the event that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the Holder, together with the Attribution Parties, being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number
of outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the Exchange Act), the number of shares so issued by which the Holder&#146;s, together with the Attribution Parties&#146;, aggregate beneficial ownership exceeds the
Maximum Percentage (the &#147;Excess Shares&#148;) shall be deemed null and void and shall be cancelled ab initio, and the Holder and/or the Attribution Parties shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably
practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares, if any. By written notice to the Company, a Holder of this Warrant
may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 19.99% specified in such notice; provided, that any increase in the Maximum Percentage will not be effective until the sixty-first (61st) day
after such notice is delivered to the Company and shall not negatively affect any partial exercise effected prior to such change. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) This <U>Section</U><U></U><U>&nbsp;11</U> shall not restrict the number of shares of
Common Stock which a Holder or the Attribution Parties may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder or the Attribution Parties may receive in the event of a Fundamental
Transaction as contemplated in <U>Section</U><U></U><U>&nbsp;9(c)</U> of this Warrant. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be
beneficially owned by the Holder or the Attribution Parties for any purpose including for purposes of Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder or Section&nbsp;16 of the Exchange Act Rule <FONT
STYLE="white-space:nowrap">16a-1(a)(1)</FONT> promulgated thereunder. No prior inability to exercise this Warrant pursuant to this <U>Section</U><U></U><U>&nbsp;11</U> shall have any effect on the applicability of the provisions of this
<U>Section</U><U></U><U>&nbsp;11</U> with respect to any subsequent determination of exercisability. The provisions of this <U>Section</U><U></U><U>&nbsp;11</U> shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this <U>Section</U><U></U><U>&nbsp;11</U> to the extent necessary to correct this <U>Section</U><U></U><U>&nbsp;11</U> or any portion of this <U>Section</U><U></U><U>&nbsp;11</U> which may be defective or inconsistent with the intended
beneficial ownership limitation contained in this <U>Section</U><U></U><U>&nbsp;11</U> or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this
<U>Section</U><U></U><U>&nbsp;11</U> may not be waived and shall apply to a successor holder of this Warrant.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <I>No Fractional Shares</I>. No
fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and
the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <I>Notices</I>. Any
and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or
communication is delivered confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address specified in the books and records of the Company prior to 5:30 P.M., New York City time, on a Trading
Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address specified in
the books and records of the Company on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier
service specifying next business day delivery, or (iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such
communications shall be: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Solid Biosciences Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">500
Rutherford Avenue, Third Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Charlestown, Massachusetts 02129 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: [***]
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Holder, to its address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth herein or on the books and records of
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Or, in each of the above instances, to such other address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address as the
recipient party has specified by written notice given to each other party at least five (5)&nbsp;days prior to the effectiveness of such change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14.
<I>Warrant Agent</I>. The Company shall initially serve as warrant agent under this Warrant. Upon thirty (30)&nbsp;days&#146; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new
warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its
corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first
class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <I>Miscellaneous</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a Stockholder</U>. Except as otherwise set forth in this Warrant, the Holder, solely in such Person&#146;s capacity as a
holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such
Person&#146;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock,
consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to
receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of
the Company, whether such liabilities are asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase
the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon the exercise of this Warrant, and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from
any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant Shares for which
this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This
Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their
respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors
and assigns. Except as otherwise provided herein, the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND
INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR
DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE
JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR
CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY
RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit
or affect any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be
invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree
upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its
authorized officer as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SOLID BIOSCIENCES INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be executed by the Holder to purchase shares of Common Stock under the Warrant] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of
Warrant No. <U>&#8195;</U> (the &#147;Warrant&#148;) issued by<B> </B>Solid Biosciences Inc., a Delaware corporation (the &#147;Company&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in
the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The undersigned hereby exercises its right to purchase <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> Warrant Shares pursuant to the
Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price shall be made as (check one): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744;&#8195;Cash Exercise </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744;&#8195;&#147;Cashless Exercise&#148; under Section&nbsp;10 of the Warrant </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $<U>&#8195;&#8195;&#8195;</U> in immediately available funds to the Company in
accordance with the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in
accordance with the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in
giving effect to the exercise evidenced hereby the Holder, together with the Attribution Parties, will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of the Securities
Exchange Act of 1934, as amended) permitted to be owned under Section&nbsp;11(a) of the Warrant to which this notice relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;of&nbsp;Holder:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SCHEDULE 2 </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT FORM </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(To assign the
foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Please Print)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Please Print)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone Number:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email Address:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> <U>&#8195;</U>, <U>&#8195;&#8195;&#8195;&#8195;</U></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holder&#146;s Signature:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d908068dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g908068g0218114711739.jpg" ALT="LOGO" STYLE="width:1.3in;height:0.169444in;">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;18, 2025</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solid Biosciences Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">500 Rutherford Avenue, 3<SUP
STYLE="font-size:75%; vertical-align:top">rd</SUP> Floor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">+1 617 526 6000 (t)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">+1 617 526 5000 (f)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">wilmerhale.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlestown, Massachusetts 02129 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RE:&#8195;Prospectus Supplement to Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is furnished to you in
connection with (i)&nbsp;the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-277871)</FONT> (the &#147;Registration Statement&#148;) filed by Solid Biosciences Inc., a
Delaware corporation (the &#147;Company&#148;), with the Securities and Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), for the registration of, among other things,
shares of the Company&#146;s common stock, $0.001 par value per share (the &#147;Common Stock&#148;), which may be issued from time to time on a delayed or continuous basis pursuant to Rule 415 under the Securities Act at an initial aggregate
offering price not to exceed $300,000,000, as set forth in the Registration Statement, the base prospectus contained therein (the &#147;Base Prospectus&#148;) and any amendments or supplements thereto; and (ii)&nbsp;the prospectus supplement, dated
February&nbsp;18, 2025 (the &#147;Prospectus Supplement&#148; and, together with the Base Prospectus, the &#147;Prospectus&#148;), relating to the issuance and sale by the Company pursuant to the Registration Statement of (a)&nbsp;up to 35,739,810
shares of Common Stock, (the &#147;Shares&#148;) and <FONT STYLE="white-space:nowrap">(b)&nbsp;pre-funded</FONT> warrants (the &#147;Warrants&#148;) to purchase up to 13,888,340 shares of Common Stock (the &#147;Warrant Shares&#148;). The Shares and
the Warrants are collectively referred to herein as the &#147;Securities.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Securities are to be issued and sold by the Company pursuant to the
underwriting agreement, dated as of February&nbsp;18, 2025 (the &#147;Underwriting Agreement&#148;), by and among the Company and the several underwriters named on Schedule 1 thereto, for whom Jefferies LLC and Leerink Partners LLC are acting as
representatives, the form of which is filed as Exhibit 1.1 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed on the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are acting as counsel for the Company in connection with the issue and sale by the Company of the Securities. We have examined and relied upon a signed
copy of the Registration Statement and the Prospectus, each as filed with the Commission. We have also examined and relied upon the Underwriting Agreement, the form of Warrant, minutes of meetings of the stockholders and the Board of Directors of
the Company, including the committees thereof, as provided to us by the Company, the Certificate of Incorporation and Bylaws of the Company, each as restated and/or amended to date, and such other documents as we have deemed necessary for purposes
of rendering the opinions hereinafter set forth. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g908068img1.jpg" ALT="LOGO" STYLE="width:6.66042in;height:0.434722in;">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g908068g0218114711739.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solid Biosciences Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 18, 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the
authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to
such documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinions set forth below are qualified to the extent that they may be subject to or affected by (i)&nbsp;applicable bankruptcy,
insolvency, reorganization, receivership, moratorium, fraudulent transfer, fraudulent conveyance or similar laws relating to or affecting the rights or remedies of creditors generally, (ii)&nbsp;statutory or decisional law concerning recourse by
creditors to security in the absence of notice or hearing, (iii)&nbsp;duties and standards imposed on creditors and parties to contracts, including, without limitation, requirements of good faith, reasonableness and fair dealing, and
(iv)&nbsp;general equitable principles. We express no opinion as to the availability of any equitable or specific remedy upon any breach of any of the agreements as to which we are opining herein, or any of the agreements, documents or obligations
referred to therein, or to the successful assertion of any equitable defenses, inasmuch as the availability of such remedies or the success of any equitable defense may be subject to the discretion of a court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also express no opinion herein as to any provision of any agreement (i)&nbsp;which may be deemed to or construed to waive any right of the Company,
(ii)&nbsp;to the effect that rights and remedies are not exclusive, that every right or remedy is cumulative and may be exercised in addition to or with any other right or remedy and does not preclude recourse to one or more other rights or
remedies, (iii)&nbsp;relating to the effect of invalidity or unenforceability of any provision of the Warrants on the validity or enforceability of any other provision thereof, (iv)&nbsp;which is in violation of public policy, including, without
limitation, any provision relating to indemnification and contribution with respect to securities law matters, (v)&nbsp;which provides that the terms of the Warrants may not be waived or modified except in writing or (vi)&nbsp;relating to choice of
law or consent to jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also express no opinion herein as to the laws of any state or jurisdiction other than the state laws of the State of
New York and the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the opinion that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance
with the terms and conditions of the Underwriting Agreement, the Shares will be validly issued, fully paid and nonassessable. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g908068g0218114711739.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solid Biosciences Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 18, 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Warrants have been duly authorized by the Company and, when the Warrants are executed by the Company and
delivered and paid for in accordance with the terms and conditions of the Underwriting Agreement, will constitute valid and legally binding obligations of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Warrant Shares have been duly authorized and reserved for issuance and, when issued, delivered and paid for
upon exercise in accordance with the provisions of the Warrants, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is
based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters
or opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion with the Commission, in accordance with the requirements of Item 601(b)(5)
of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, as an exhibit to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be filed by the Company on the date hereof in connection with the issuance
and sale of the Securities and to the use of our name therein and in the Prospectus Supplement under the caption &#147;Legal Matters.&#148; In giving such consent, we do not hereby admit that we are in the category of persons whose consent is
required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Wilmer Cutler Pickering Hale and Dorr LLP</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">WILMER CUTLER PICKERING HALE AND DORR LLP</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>d908068dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Solid Biosciences Announces Pricing of Underwritten Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CHARLESTOWN, Massachusetts, February</B><B></B><B>&nbsp;18, 2025</B> &#150; Solid Biosciences Inc. (Nasdaq: SLDB) (the &#147;Company&#148; or
&#147;Solid&#148;), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the pricing of an underwritten offering of 35,739,810 shares of its common stock at an offering price of $4.03
per share and, in lieu of common stock to certain investors, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 13,888,340 shares of common stock at an offering price of $4.029 per
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. The aggregate gross proceeds of the offering are expected to be approximately $200.0&nbsp;million, before deducting underwriting discounts and commissions and other offering expenses. Each <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercised
in full. All of the securities in the offering are being sold by Solid. The offering is expected to close on or about February&nbsp;19, 2025, subject to the satisfaction of customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financing includes new and existing investors, including Adage Capital Partners LP, Bain Capital Life Sciences, Invus, Perceptive Advisors, RA Capital
Management, TCGX, Venrock Healthcare Capital Partners, Vestal Point Capital, a U.S.-based life-sciences focused institutional investor, a major mutual fund and a large investment management firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies, Leerink Partners and William Blair are acting as joint book-running managers for the offering. H.C. Wainwright&nbsp;&amp; Co. is acting as lead
manager for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities are being offered pursuant to a shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
(File <FONT STYLE="white-space:nowrap">No.&nbsp;333-277871)</FONT> that was declared effective by the Securities and Exchange Commission (&#147;SEC&#148;) on May&nbsp;17, 2024. The offering is being made only by means of a prospectus supplement and
the accompanying prospectus that form a part of the registration statement. A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the prospectus supplement and the accompanying prospectus may
also be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) <FONT STYLE="white-space:nowrap">821-7388,</FONT> or by email at
prospectus_department@jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) <FONT STYLE="white-space:nowrap">808-7525,</FONT> ext. 6105, or by email at
syndicate@leerink.com; or William Blair&nbsp;&amp; Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) <FONT STYLE="white-space:nowrap">621-0687</FONT> or by email at
prospectus@williamblair.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall
there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Solid Biosciences </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solid Biosciences is a precision
genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich&#146;s ataxia (FA), catecholaminergic polymorphic
ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and
other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease
management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid&#146;s mission is to improve the daily lives of patients living with devastating rare diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995, such as those,
among others, relating to the Company&#146;s plans to consummate its offering, including the satisfaction of customary closing conditions relating to the offering and the expected closing of the offering. The words &#147;anticipate,&#148;
&#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place
undue reliance on its forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements the Company makes as a result of various risks and
uncertainties, including but not limited to, market and other financial conditions, the satisfaction of customary closing conditions related to the offering, the Company&#146;s ability to advance its product candidates, whether our cash resources
will be sufficient to fund the Company&#146;s foreseeable and unforeseeable operating expenses and capital expenditure requirements on its expected timeline and the impact of general economic, industry or political conditions in the United States or
internationally. Additional risks and uncertainties relating to the offering, the Company and its business can be found under the caption &#147;Risk Factors&#148; included in the Company&#146;s Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2024 and other filings that the Company may make with the SEC in the future. In addition, the forward-looking statements included in this press release represent
the Company&#146;s views as of the date hereof and should not be relied upon as representing the Company&#146;s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the
Company&#146;s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Solid Biosciences Investor Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nicole Anderson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solid
Biosciences Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investors@solidbio.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glenn Silver </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FINN Partners </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">glenn.silver@finnpartners.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>sldb-20250218.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/19/2025 2:50:14 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:sldb="http://www.solidbio.com/20250218"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.solidbio.com/20250218"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sldb-20250218_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sldb-20250218_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>sldb-20250218_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/19/2025 2:50:14 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>sldb-20250218_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/19/2025 2:50:14 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sldb-20250218.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g908068g0218114711739.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g908068g0218114711739.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  0 'L# 2(  A$! Q$!_\0
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=OI7AC4KFQ@40PS2GRF=4^7.U@".G<<CGO0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g908068img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g908068img1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MD!)HV)Y # T $$\-S$);>5)8R2 R,&!(.#R/<$4 24 % #))8X4WRR*B^K'
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MJ01ZB@ +!<9(&>!0 ;@&"Y&?2@!: "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /./$FG-IVI3PV5JS22N=1M#&@X^7;=)GMN0Y'JS>U
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MD4"-77(W?>;<0.>WKQ0!7MM5N+'Q%?21SVTL5SJ=O!* I&XM;I\RG=QR.G-
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M6NKR6*=2$6=<QJIR@$ZA>=H&"F2>3Z\"@#0T"\O+HW*W;,Y0J0_E[%YSD $
MC&!D'.,]30!M4 % '%6(GMM,M)M*M91?16;FY5HV578)P&R/F;=CIDXSZT 7
M8KO6I[=REPVV-)71UAR9"H0J#E5[EAP!G'J* "\U/6D,T:1&-8' DF*8!5V!
M!7@_=7(/!Y.: -#1YM1N)%>\D(C$"D*(\!V+/R20#G:%XP.OTH V* "@#EX+
M*\BDO;J)8XYI+THLGD9E"&103DG&-N>U "+J&K3ZA<6\3RI'O"@M#DQ@2A3_
M  @<KD]6['CI0!-;RZHFJ()M_DLHB><1\DB20+\N,#(P2?IP <@ 9I]Q=Z;9
M6EFRRO(Z0$$P\DM(?,S@8X!!.?K0!9TY[_[;8->74S>=:LSQF(*N_*\=." 3
MU- &[0 4 <_+>SV=SK2Q)(UPSJT"F-F!_=+R.QY!X]10!"MSJLRR+;W<K11B
M1HYVMP&EPJ$ C&/O%AP!G'MF@""ZO]3-V'7SA*CR?N5MR5C3;@-G')P2<9.3
MP.E $_VK5I8I6M[B5HH4E>*0VXS/MV%01CU+C@#.,B@#IATH * ,O6)3!-ID
MQW^4EUF0HI; \IQR!VR1^E &=+J>H-=2F"20<OMB-L2JQB,E9,XR3NQQGOC&
M1F@"[IE_<'1IKFY66:2(MC"\R #(VX SZ=!]* ,RQ36+,M:R))"]R\<IE4B4
M!B<2XXP.Q'U/I0 Y]3U*&YBBFG=&5XD \@$39F*,6./E.T CIUSSV ([:\UJ
MZ@#S1[YHV1_*"D;9,-E,[1QP!U/UY% #5U/6?[,,C3D,'7YA$=Q.PDKS'@<X
M[>V<\T =9$Q>%&92I*@D$8(H ?0!E^(+=[O2?(0R O/""8B0RCS5R1CT'- &
M$]WK%O<7197B;SDCEFVG:<1D[D^5N&..W&<=: +3:IKL(#-:F3R55Y%2(_O
MZ@*JY_NMG/L!GK0!>U6VO!9VEQ#,POH62-G1<AE<A7.WV^\/0J.V: ,ZUN-2
M1!:022J5^1U,.?L^)%48)'S94L<G/3/M0!HZ5)>)?W4%RKK%YDC0DJ3Y@W<D
MGL?0>G//8 V: "@#F;S3;BXUG4+I5V"+RG1UC)D.T9*H<@<]"/<T 5X;_59K
M?SR)'DB=@K^63A2B9.-J[L9;C'48YH V;*^F&FW=Q)YMPD+-Y+>7M>90 >@
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MR7&3,D0 4%). &48_AX(.,CDYX )5FU>:,%6:V<QEW98!\S")"!S_M$C\,4
M5KC4]3EEEA6XEAF<2J(D@!V@1;E*MCDY[<^F!B@"234=4#2"WFEDE"ML1K?@
MIY65DSCDEL<9[XQGF@#=T_[2OVF.YE:7RY<)(R!2R[5/;CJ2/PH N4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!"]I;23I.]O$TR<+(4!9?H: )J "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H A6TMDN6N5MXEG88:0( Q^IZ]A^5 $U !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
H % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46074015604240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 18, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001707502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 18,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Solid Biosciences Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-0943402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Rutherford Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Third Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Charlestown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">337-4680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLDB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MLD6R[[KL*3<1**P<(9OM(,TI4_-J]_=(\Z9A5WO9"$M+KB*!C+>QE(I"K N
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )&&4EI[B\8;[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( )&&
M4EJ97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ D8926NRUP)]C!   .!$  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( )&&
M4EJ?H!OPL0(  .(,   -              "  :8,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ D8926I>*NQS     $P(   L              ( !@@\
M %]R96QS+RYR96QS4$L! A0#%     @ D8926APX9>H_ 0  / (   \
M         ( !:Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( )&&4EHD
M'INBK0   /@!   :              "  =<1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( )&&4EIED'F2&0$  ,\#   3
M      "  ;P2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
'  84      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d908068d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d908068d8k.htm">d908068d8k.htm</File>
    <File>sldb-20250218.xsd</File>
    <File>sldb-20250218_lab.xml</File>
    <File>sldb-20250218_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d908068d8k.htm": {
   "nsprefix": "sldb",
   "nsuri": "http://www.solidbio.com/20250218",
   "dts": {
    "inline": {
     "local": [
      "d908068d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "sldb-20250218.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "sldb-20250218_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sldb-20250218_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-02-18_to_2025-02-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d908068d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-02-18_to_2025-02-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d908068d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.solidbio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193125-25-028691-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-028691-xbrl.zip
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M@ZE]L@>8(XBZ_;F)+K B+\OL;B6;E*:/_O%#L^8<G2@2,I^-AR)@)-!N2)'
M!/T(#1&!\)("$P AEO,/RMLYM-N08^J YD/G:'^><=>.ABX$$/X:I[9I '38
M*)S5ZT>EQF%S>02YM8S;>@RR'=?L$Z@<"%1,NE$2>VGY'UAC@"G&X(YYI(<J
MC5Q0%9(;70AX2SKNHESWG-BCH6+NO2XLT3$8A['D&'/VQ2/I,U],D&;X$$GY
MO##I8JQF:#+@/NH KD AA"SP@.:A((J/(C^D 1.1\J=$@0RIP52/8%\0?4"7
M<:9MP4NF2>L(^I&$!M/XV0 <6C'!]]"P<0S*%-F;5\CZ^S$'Z\3=PIEB+ ;S
M%Q8P">JX&\ 0D0ZMR7FY5C:SWS]>RI6'Z[KN6W7-$W\\]='G@X&98&$EJUE8
MY,PW?CIYVB(B6S^A4G^7/ 1>P  Z"FS(I#;V:_I"^'T*?! "UV;5[@'BOW74
M:)S,:]V7!;YF7AD^('G2DXW-[]Q@%E> G"RRR#A3JKZ)@)T:M0,K%C/%8:P)
M[SE'I/WIAM3JU3(T?$EH^L;?+^=OK JZ@/W@[C,H4="D_NZ8^_!;9NX44="U
MP=0\9S]K;9P&+3FU6).G0I!;%A&+P+.]U1K5LNEQ/^.4O4G+SJ3E6C*T!%@^
MUTO!T$F0$ RMX6JO+#5'W[+4/,O"@-&2FT%I+!K/V9 5),TKU?;Z^]N5-=/G
MF[1]"6GK*A4Q^2HRUWR3N;5DKLY*C3UWNS)G^UQ9YK8=;6;\4Q/6,0F!X7CI
M^DM4$'&L![-='HY]]964MQ4X+TN]KI!G63*#.=[?J(2YBZ+A+6[L,TMBW2%Q
M?:K45JJW:^/L:ZOQWDJ* OC%J[N]Z0@>O=$F.WB\EE3S+K.FZ(M32@0$!!\@
M2LU*WKA]+47*I;D#8QFG3JVOU<,&Y896X0Q=/4!)+Q3N/?FQ"MSFD#&5Y('Z
M$2-CW%LY7+CZ[W56L"U#@I5[(W;K8^ ('.W>Q<</7]OT8AK'#MQ:Z]!G_6X4
MP;F*[I&#)7Q&+JGRZ-_D%U^ :PZ^E0_>%?E,Y3T+%R)G S]0(X('N!X&@Y67
M^87=P$-7F9'^E+BZ(@$CW(-(,[WR;:8,P!4!7Q?<;03BCMQ),0F'Z'&/L31
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M5&\5FT[51"4JAX6>OI7,VD*=0:]>A^::@$=AP%/,A#IQ[!-'/+,T2J*D%'I
M(MI@XG,6X7"Y6 IFY()84=PQ&3S@ D^IBL\[<(#YT@#QX,6NVX1*M.%VKL]V
M8"'&;/.G7#^_VWX2! &$8)/!W((GX-2+S6:S6&\DF)V=3Q8=MBN2QWB9G/M^
MXLF:7I#/5@)[.;RX.I#TF?8J0#>@KY.A:YE@])(PR1B<-#8# [B]/S;*U7J&
MMC%8B]_;!%@[6*V5&4VSM7&B="YD_?[-;+.R!*X=:#^M%KP<13,(&$@QRN(L
MYXJ%V0YS^H-0^)MBYL=Z^:C9K"W XB;XVB)L1[4=XMSUA;):*,<X0&_V.#:>
M-4),[QD9^Q3!"M!+IGT1A;/FH16;!Q7U_\) V\[5K'*C;KRHS8U ;8SPC(%X
M>(AX/.VC*V/G%ELU<SS#IF;M-D,5T%\<%V H@!-0C\ &+$3GW@7&RY Q0<R$
M@S+HV\6"C_IE?TI^=)I'Y0.#!AC5AYF 'AT )T,H[N&R.G@U9_$\KG14872)
MFVRI,M<Q7%XZ,)(C4.R5$+1%/1=CC&/%-1\O4>!JY@^2D$XSB%ZFKX4!+E9;
M=MDKU>-A]_26L&??N!1E0ZUZO5ZJ'8&4.4FA4;/"1&=17)^BSX(^AK;^L9;.
M)#0014ETEVZ-RYOP3CNUWP$X>K'$'&F):8")09Y3*'"1 O$9CWV#@JPGD>-#
M#'W[#/R) <S7,[Z0AJS3WCV'=#93/1IX3  \,NE"L&T57JKE9HTT^SL"!PU0
M,.O-E,FFH,3<:6'1(18J85 .(((LU0">/<4%V1B/P#3Z<QN"D1FZ2*P6$N-8
M66HU/P0/P>PM(!/XKA>7PW=P\\(B\N2(T4#[-I2X5 U3S**JUK=\W( 1WS:P
MSZ _EG6SCP$[6^(R:0P@GJ*QR! QAG4#8G"5-1W9]=C4^PN,AA8)F+=.\.A#
M=-":6'=4N[Z@5S$M$WA&,#U4*[P?:=-2M$W4V.=A<@6JM\\#:EM(IJN1R89&
MA1A4',0 /&H])'1LM $*I3$E"6IV+WF_)8L@P+:,U!9<NV+.31G1J<ZD&8UG
M,VDI@;')^F/IT +XT7"SX7\<#&4@T(>]:F<C&5#[34+&DK#9X%JM%PW/W@&3
MH$FUDQ3 =6XJ-$4R$1%XY"Z-DXGT#ART.^3#9X6CSP*(WC%O"&Z!F& 2'N13
M]V^GO1>*.Y/5UTJ;&X[B/O*YVC<(0.^#-,JMUD_(?RW\HD/8.-EIS5"L%BP7
M/ L<^&PZ@ZD]O!%$N-RX+\93F<-*EOIZ>#T-4+Z8XZ)@[G!^4@WY&"778\B2
M<=D!DZ;20T69VJ8ML6S15CHS@"#; A>Y=G.-5:(&/4F(K)&'O*0]CR&_0QID
M.D%6Y('&OMFLYFC$&Y8Y=, "3)7M#-NBSK1(2H*V78M_%Q#K&4]9&X-8][E<
MNM'(G,VL+)-3@@$W19V)QA/3X,8%+Z8B")/<B@7+2"]H4 :>4G'>.FQ%4=US
M5"'X;X3NLV;VQ!DK&NL'(B.T@*']  Q-C4N7%4(CX3K(M #CE3: TP3HS7W?
MK)"!)0/ +,<L)0T*"X96J&^D9Q)(4^*#!0IC@Y3!*E:*:"QR&P+[.H'%DKC7
M3D1E8L-LND[;9ILQ,G068(MI'#XEZ4,UDT8I9F/-),;422P3>>IB$QL%Z0D&
MZ?ZK1%7%QC'VD+*)BNQ^3RPL@1KO@R[7H<'2;2FVZ*IU*G(!4*-H67;!\.CE
MQ9&&4;$&TG3'E_'GGD"8#3)CG,VQS1*J3)A$W>IAU \<C/.#\&TLE+$M6J#2
MU*VFA'E@#E9SM=.,@& _"OQ6VPD.:0QE.#O)V!@GW1JGP2KXC'>8%0F;)](:
MQS( 3E%2XZ;9OE^'P;'0="=TB,^4*_DX1\N<"5R6 ]I"T.T);<XTM:3&%^8L
M3-F3A<;9QT@+ ZOD"#P8E$NMS"4#I=E'&;1GGC^7MK(@ZW!](Z-B;3O"9B);
MBFL&AKP/K.*4'1MNF^L&7&.&/A3HN.OHV6;HX^GQY(0>U.\FF9^=UNY9XAQP
M/DZV:_J@U7T([GB  FR$,E VD/F=^[A;N!V!*97DFKOW)M3_E?J&8!^%E.3B
MXGHN*V"R-<7-4]*6C/E$.#IW<[0X2' _A\,,?M9>E?Q6Y<Q4.9O?>)73G-[5
MT='SUU7'S%IWFY_$]#OZ_R!CC.H@- !'TXW#?<R5+$B88P8O*^CY/F:2=:D8
M&7A:+1 F+<H@:>U(2E0(YE2 U7.@F:WG*,9ZW_D&RF\71VH4SMI4IV+0';L4
M8(9NM)>+^(1)@KOBE2Z$N,?K7IP%5D] N17VN-T2UA,7UB9]!W9&OIU1DM>.
M*XO:U[<.&";P+%NA$W$M^0.F&S)^XP5\V',!;G URRCU)%NZY()6$^L80@?K
M$/3?&9=2%>?L15+:65+^,?[D1.!")SL;]"/QX):0%6/P[9,^\SE[F+N-Z.!!
MM. ^1%ZS-^-ZQ]Q]#>CL77.@PNQ=<!%G;XU]&LS=$_AC09SZ<P\DP[,%YV^+
MOQ; H(:+YA$"+[*YMA@F)_?,TJ/,LJ9WY-WWO;)I5P=$0]\Q 9!6,0%0.R89
MW4>MJ$T0H?W%]*@.^U,Z.F)9(L@@9SZ&ZW=#[6U3WW^B<:P@4-+ )L3=ZZ(B
M2IH1NME$+(0PD<XE4G>(8F:L"_"UCCPU*]LLM9$5&Q%A>1%D.SW:^LE) $:F
M(B*&ITW@H&N]X"5&&%="4!N8TN_37951)V&I!I :^:$!Z\%.'KOV.&J89,\[
MAH-Q?65^3KH0NG12YO23I<C.)[7O,02&OQ8PU'</5'(1@8WFZMZ,!5;>I--,
MBB&-Z_M1J)&B0T[-'$6](I69P,<$[NEZT3314'QQ^=NH:EMTS];[8M><PY2,
MWK^S)[<P>%N,N*M3&= U](MQNL DA)L#)XWV]32TB56FE 3T,%D%)$H93RSB
MYFH9?I96)O-.E79%,"T3P431)7+!GO:1<I'N,4Z0N-04O*S WL"@Y!-,5"3+
MJBP]4N+/KH#Z3Z0/;P>>>JD1=ZJE_R3']MCTQ-^F-V+408^-@;'ZF$S61>.J
MJ=L6%P*RN)([7Z?5 "YQ3+-\A<<"918H9#4$<G:^SU@RHC#"\F@N8?R,R.01
MO!VG*,E)+<34 V<397-&28T5/55=[?&R"JEO]%"<Y<DNY\M4XI;VC@C3O:NH
MK]C?$4M7XF0&S:O@U.51<0(Y>3<N!6*-$;[[8FQPJ#/B:>%H,4B8?M25BC+Y
M54QP^:$N:?ALCKYFOPHN:Q]K,(WI>(*&"*48@385/"V5&F;("V:<HM-*6"M6
MRD?*'"V5GD %(WL">GR+\7<=X[>^\1C_4V+^,I%;)EGW)0)_;S\9_0G^K>UX
MY_QV^'N%K?/OWIG-\_K#J]C/5;:[SV^MMX<7UU]MN_N6]K*OQ/DK;$4F\2_$
MFE_/+?5]X=YO?=.NY<[3OJS@BK0U]EFON%'S^T#GQ[3@DM<U5C(6"/\<'\:'
M8<*#RM(GX%.CY ?O"[4O>;CWDG7RN+7,*3N[X208%\P:)>;W=;U6M5D];'KL
MT7'*PW!D%RC-%8B*VLOREKJ[_6E<T\_[<OKN:EL\0,/39=O=OP."-UZ;X U+
M\"V4_+YORAV\-N4.+.6N;!GR1:7'[Y16M?J7HE)[G0+Q7FZ%1Z[8!.RV_[U2
M$0MMKTO%5LN2\5H7!&]L0? I:_B]$L>I-G9(F[9X0)G!=9Y=]!:IV<_QD8:4
MZ"TC>^88A=#49[O:3R5_?+BYV,_XD4^>RIBKF2ZO861CR;="T&L4@E8[ZJK[
MR^7Y[6\WG=[.UP1=S^P%E.SOB$N;,UGMR)3\TL%P_E@,+_*G)A'IF62N_35B
MLQ),P<QQ<YDIZ/39D/J#>.6<3LK;!I@6C7##MNX.Z#04$B;I/94/_&;S*;,9
ME#QK-W229/6<RK(C!%?M9O';!UL"HI$D=F9BXU<P (OGM]E)5#OL,S69== 2
M5Q?=C^1#]ZK7[G8NVYV>Z:M[V2ZO;[)19);8;/TH;[2WV^R+N  Q(?#7S(^7
MN$';/JML%QRB/8L/T^,=P?K"$P6?.5;GA4:JHBKDW&>/5-=HV]&H+[[L@8+?
MBMK03($GV^V,+>;(\D:2%4BB3Y7<&4W:0\X&<S]J)A?%#K-._VFE+[PI7$.@
MZ)_]/U!+ P04    " "1AE):ZC^/)""8  "N 0, $    &0Y,#@P-CAD97@Q
M,2YH=&WLO>ERV]B6)OJ?$7P'1'95A10!.R4/.3G+$;)LYW&7T^EK.^M4=<3]
M 9*@A#1(\ "@9)ZGOVO<>^T-@*1DR7+?<D?U24LB@3VL>?C6KW_[\/OKI[_^
M[<7)\Z?CT:\?7GUX_>+IB_^Z=WS_^-?O^2?X]??R]^379W\\_^_DV6^G?[S^
MX]V_?_?WO[WZ\.*[Y/V'_W[]XM^_*XME?N\\+\[.VU_>5/4B*[][FHQ'\/W3
M?-GF]=-?G[_Z3_WP93%KSW_YZ?[C8OE=DI7%V1(>D,_;[^@U;_5CBZP^*Y;W
MVFKUR]&J?9+(SY.J;:L%_VI>+=M[3?'/_)=C__,\6Q3EYI</Q2)ODC?Y9?*N
M6F3PII/7KWY[\^_?U;C([Y[^^NSIBT_GQ:1H$]AP\NOWSY[^^OU;W''? HX?
MW. *IG0DWSU]_\?K5\^39Z_^>'_ZZL6;TQ?ODU=O3N\GN(S^8_CA%A;Q\''Z
MX\.?TY^.C\:C]^=9#1^NYLEIM5A4R^1]6TT_ILG;K$[^,RO7>?(O1_>/CHZ_
M\!*SY2S9<C>W\<I?7_[QYH.CU_.BS>\UJVR:_[*L+NML]=W3MW5^[^5Z.<MG
MOWZ/GWV:_#VKZVS9-DE;)6_7]?0\:_+D^&'ZTT\_I0\?'27]A_O%-_;GTS]A
MU?5E7;3%\BPY.:OS? %_A(7\^<4X0'CP93ZIUUF]^;?EI%D].?XI31X</7B\
MA;IN9!%/_W<^G^=U ;]\_?ITVP7<A-AY^CJ'=RT_(A.UR[SV+[W-+9XTR;M\
M!?0&-YNUQ0437GN>W_IVF_PBK[,R<52&6RZ+ILUG6W9](Z\NE@F0]_OI>3Y;
ME\![2-')>5[GP)&W3=E/I]]729>P;G&WCQ\<);]GLZ(!47)RD2_7MW^W^,__
MKFK0"/JOY/CHZ,&#6R=G/-Q!/KK-'3]^"&(Z:W/X7Y"3;9H\.OKU_9_N=?Y9
M/S[^UR<)4'Y;3+/R'ADUO\ JOGO:GO_Z/7SC:?*RK*KZUA?\K&K::ID"931-
M-CU?-WD+*NGHP?'1S[=^2Z^!&N$WJ*Y_ [E3HE[YY3H*KLT_M?<*$"#+]I='
M_WK%5;RORF*6/"NJ9EKDRRG\\=5R>C]-LN1Y7F:7H(23:56OJAKD(K#. 0K%
M?_M?QX]^? (F(:CF5;;<H#6(O_OIR6&:K.IJ534Y*?:B:8#/<(=-7I;X&_RZ
MRKQU5^:-1]ND4OAR*S*#%<R!<"[/JT6RJ=8);B";DO+.FJ2.I'SXQ$@'! \]
M* YA(TEV!A; &9(X* AO#":-,U>F;*XT; NNP!:\L+;@*J_YPZFJ&#G$\2A<
M#!M 9@UTCCLMK8.B.&0# ?9R;Q[87)?&YEJIS15ORMA@_9N*U@VDTN)#\D]Y
M/2W@@:NZF.9)_H]U1C?>W3=<,7X?KFDQ'F5MF^%EZQW#)<']JZ]Q2M<?'HQ:
MCN9H[B<?X!-B,N(QX1><A8DD@$^']]8Y:)P:WL9O"@\\GZ[1S.-#O\^/I@?O
M=0Y$[-D$:':]JLQQR*?L:L:C/98C7T@\'5Q]2?#8":Q@W38MG KQP!S8)3DK
M+O 'U+_3UK%E5KK51D>Y;3/!)F1?O)?QR)\MKL[N0<3<]^#G@ADM7B_XL_1_
MOZY@.YLR#X5NONA(/_S5*CO+[TWJ//MX;Y(#3>6_9.5EMFG H_[U^Q6^Y&_O
MDO>O_@_PR\/O]+GDE?_ROWZF__==\O=7SS_\[=^_ ^W\K\[H/GWQYL.+=U_$
M+_\L ?[!W#<>_V0#)+&<%_6B20J\(N>R7!;M>2"  Z,3OC3-ZR72!=V=$1"S
MD#8<GZ1XT?.J+*O+YI=K>+F?M>_C^R@HWN5GH#A$.9'M@5M%J<$RP9T,K!0$
M(HAC(%3<T;PHX5_N2/RF0"3!GU]\@LTOS^@!"^#L7MTG?[ RFG1:],3D!)@,
M)>O/#Q_2D66P1A#+J>.O&E0=<QO(X75)NVD,,^L*6KQ@?L7!%,X=N!<450DR
M>$"2X:L#-9;A&_R)-7IB2;4<CUZ"1-ZM8=[?>Z@*Y> EG.+N;[RI[K-*>OCP
MX;T'/_[XTX_'AZD^HUA.RS7+)K0=FA5L:@VD5>=X#DB-57R>D807:74_>;^>
MG@_LSYX[*BS\>@LD!2PR'DWR*?Q)Q"$<:&H6A1\LEJBKZ(GPIWE"6F^&7#5#
M/0IB?TE2]!U:+(\>'IVD^+_/$K!#X+^GPT3!\AF(LM7+'K@=NV+X)/*U6^TR
M;\"0\4:,+ +L.+?J@ 2*QHGL\2B6V=88ZN<L?=(3N@;X%AC-,WD(TR&(DX5_
MSENXR&)1++-ZD[QU]^N?DRSR#(@]!RO W+_< #P9EM8,WVMR0*L #J?+Q5\U
MS"9M=9BP0@B/"KD.C"WSJD@4&'[K7NZ#1P?9%BY7RAS8"/ZI_UQWWW![#A^I
M%OB'OBN.I-,SD-SC4=]Y'WJQ$U_4X.7@A_&)Y@+[MMJL5ZN2MW,%[C7F(%Q%
MW;1,40? /8ML!OKG(BM*;UC58%GF#3&,JBC07N:FQB,ZG^,?'P[>TR&^%!3>
M$L\7GDEW+UJ33Q.>CCJOZ2J]^\FKT,A"U<(DA*;T!$R1BR+#^,T Q7:)ZH<'
M!Y,M1!4Y*?*5@)#&HQX./21V7!)W$,>C?Z?L+O=B2*"?,(4.P-X$!PZ$E8@]
M=.Z8L)D[>U?EGW(_.0D607<.@FAM@ZO>4CF@/[HMNZBKU;2\ ;CLWA<2ER?]
ML@?E,N[=_*9G>[18,LR7,[=7_-JLFJY9SL!OQ36&KTSL_EHY97O7KV!ER?$#
MI*@K*]H^VAB/@#A(KPF-.GF1S,27VR)OY STDW2)^QY7JLIBBC)AD6W@Y%BJ
MA*0&F^8[)-G,%Y?:7QD"@Y?P'[P0D;\0<X)^7WE?Y0O?.C[4W[KP.CE2=&QT
MAKW<ZZQ(;P$^^BP+$!3V?B:@?7/ -:A%T&OS6Y[DNPGY?G*:K8H6O)Q_XI=R
M="Y(2D_6;;*L6GC<O%@Z.T!.]CR[8)9!+0(<WJ#CF9/LH8/CY^S0BWQ 5I=M
MR_D-AN8^R]<X(7Y9U455J^ \ 2HMIJ26\.-@AS3N$"8Y>$0L?8V6F'D'A/4=
M^DTH]PJKQ>V=$NG3E5-0)?YLD[>H-8$[*@J:G8 ^^Y2<H/,34<-;^?;SHIF6
M5;.&^W^;33^"YVQHXY=>-3\CFAA(/>'ED.'&;YJ#F+ZGTMS;!<+']H2Z.O#H
ML6<AT&:1NI:,2&>?$C7Z\A3A=5-(!QW3Z<=?CHZ2D_N_WS=9@-.BW9"EE[+;
MU7NX7WY/#\BC=LG8CN7#7C78O[Q0ZUZ3ZNX-^88",8P CT=!!()<].JB<,8R
MV !.]:>>V,R7\ #IB9.L*1KO1/DX+HC15 .?:GTZ0Z,Q/*1N$*Y\/?G+!,;
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M=3;7!BLV#C60L0XF*?8=8F^,($W96O'KL^:5>"&T]K<XI$^B5C%_)?818:7
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MW6=BU \5%@&&LM,<="D0;H#SZ5VZQ,7[C*T53+I(/?B "+U)A1<-*V%I6'5
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MJ9 _?6C,^E1ZO)UIGBA"W T)[^N:BSLJ+<#K(?^(W 7C(-V_3B%F5/+<*2S
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M!8O- <W0=:!-!BRV*-8+_P>L$89C>B9>RF_K#-%B-[!PMM<+GDS6E\=,>!
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M\\JJ9L]WA2*TP^*]";FH[U\#(CQM'N'T?=F-&S642H%C67JO,$A&^8^&QM!
M809*LJK-Y7M2L[#5Y NNG4WUSKU_<TYOTQ#!IN>>MK\3O(??JV6^25YGQ.8<
M&+TT95X^?C98BMGI>PWS\V:N3,N0>K2^/E?!X%"8X#0&/S_F^4H3X#YC$$)+
M6$>R:KP50U6E8JVKE+2BSP2%O>P.@1=YXV9]"SJUTI^:<V>DX/\O< J:62%O
M<&!>^Y@^<F"-0?*EU&RO,]1ZA$?U@LF,8=&H :,N+@>Y2BY.K,,'4M=EE-<2
M$1?9T#^15A#LMV%+;B,RT\HI'29VE L56O@&;W;@F:%#![!G26DP'C>95#-W
MY,9=Y)2+JMKP:MPTCL[HR[A\='B'IKM^OV8(CZ;T%;@O?_VE[@O8'_.2$/YI
M_^]=T[QV-<.GKNK*], /,[WY2,]7ZYP4=FX65QIQ*UPED.9P#[D;J> Q!B+F
M2@QOL83Y\_[[^]: /]AACI"%2*=G3< 3KL$XU7HPL=+PV<_=: K]]0>,'ZU!
M,_M&ZS]>GIS:4);LJN<!%+*4G,?.A;(5D0E0?))IKQ)5IE"P03^!*06Q5N.&
MKTE933_F.FS4B0]CAKX1 ><ZRT^K-:B2TFSPSS?O3P/I0R4$:[3%P(R$Y^"2
M_P:W_'OV%YB9+OC9<U9_^_U#=%1,=XCK<H&)67/[*I'&HZ&8HN.L8'5+]DOV
M)$Z$;)+^*/+)F-1 9A%N/[EA"=7VL!&.2:Z"PF/:Z!03M"-FM[J=9C(^8@_
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M"*'X#*6EH6A]7X)!/(W6UE1R5)O4UDJXC(@."I>J#/I*7E\(()$,RAU>2A7
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M'$9E_>;ZD4"WHEY&TN%2/WK!SC )W;#NCF7/<KV8</8Z^K*# !-54FY\S)&
M+20^0[_H#9JS+LN7]VS@.(S2]#LCQP\&:.:S:.0QX4V=8LX'F*F+-V4U&H-.
MO8C1.I 1L:VN5BD80%!YL*F[K+K*#I-71J?:7N:P>5D:58+693/(-E<9!A*-
M"R#F6&.I7T(^88MDCH:=-LMZE F#UWZ5<03:;LOP[BS,&MM3HRDC"^T4.":1
MY1B/Z%IR0=*V23L[>DC=A(H:2X]PGCHARO3E+@Z#U)6K-4X&SDRC14LD44()
MEED/;$*;+6\I&P&3>.<\"D:>%1IQ X@.+,AT7:W/SFFNL*D/LP=%^!W?@B4W
M!8?':>'^CC%.@AB0+':4=F$=^/3U'OV=&&)CSQ:DY,ERF7]*3E ,2NONBFRS
MP2Y8!#ZC&NQPF@_^EE/*T=QLTT-?5QDJ0$(3"LOU\(-#G.*6I'-!K)PF#F5D
MAKYLHHP!#IK\*7[.>(H#;XS0+SGWT1AH*UT\"D?OK=EU#9R]<>#NOFIW8O5'
M&B@0C^M%-OC6%+Z+RJVELF8_D4<U&(1[B J@+YRU7I8H=MT,$(%O-LQ!T ).
MJ+$_,_#RP8##<&7=>!04VJ,%3%MDC05**&\]##:;34LM+5G@?AQ[/2/VDE2F
MK8WH/\K.DBA?-V?\3/Z9;;8()XGP=<S,%%FB%@MK1;6[,!G,@*\Q("O<0&4>
M$&+)>K<U%6!1<P"P'P^N[@N4&/EJ;4Q3__B[YX,I\4$A;K9)/9#JEPY<T\',
MRG8O:(!>4%Z'!73@6*ZO <6),=/-:U:AXY^Y9%EZM('$]P(T.MSJR-V.5?X#
M6^7:544<;QF,<^?)'^#LG,EL-V(;].8J]TN--H;@K[X8KQ,3ERRY;07+&!B&
M(>[%Y2X:FW0B:SBOR0ACA(VX]@&=OQ">ENT_O]+&ER=IDPX+!RV4,3@?KM>L
M^8HP;$U0P'=T/$DHY5JMDC^PG<Q-7/ULW!"M*$!#5+Z8B@V_#3Y@%V+'H/?A
M*AATP1[_2@$, I/"J8N(L_;%0N7W>51H@6GR>JF#X3+L.(F>H< ,.4L[#<3/
MP.GU0]6BL'QD  +9<)<<(SIPMHLZ9YI^L!NP@WN1;CI'Q5#;3GWS5DS*PH4O
M3;*\$]"]:RTS.:1$EUU7)1,O)5+BX%D_T/:ZG[MTGXNKQ<2J\N+,43?UD7(&
ML,8B!A6(9A(A2R_NSO,UA%9B>HP.6P 7+D&'L>AL4ZX,XOJ&\<@/[<QM7URG
MSLB#\&[=P?!2[_ZBIU*8,AYU!J^<4C[4R4S7A>Q;C:G/M]VLHLD<D0=VKJQF
M644PA[C%T7<LI]*CW/.RHG_DT-:6S_R3=>X&T+5(E*&Q>]A7:;3?,Y+.(Z2M
MSG5=RVK_6L_.%L:([G:]?L06MA9G=9A^)2KL(>@X[8@2+=,%T)9Q\M0N/CA-
MOI)Q3>&$1N$V=E]$CK94$XCH?&$F@81D6+![Y3*N;T4MMXYD^ <+."WU//62
MS4OO_IY2'DWHQ@]ME6/HD/DGNW[D\R*?F^(&$;;$UO0GU-%KP2O2OW7E-&80
MC>Z%A1;<PC%=4SINX*N7YQ79R;NSA>&\QS:>T\>Q2/Q]49LY5G8(MHNU"&8C
MFY19*XT(JF1(\DVS.I^ON30'<3US;6*\J=I(.[HGP+T*%J/SU0+%#0YEWC)F
M@!'D3?)0!S0\1+)215SWJ+O!(76Y&PRJJ6'78EL@TI,/"L9G2,*M933"JY@9
M=&>!EMZRXO'HJDN6HX^*?\ZY_LI8@ 0N[K,Z6Z?X:?,I&Z3>SQK^%BK&MN$9
M\)RP%D]05*M[H''O!/90YQ-TF1DQ2XHB@L;7/G%+( X[ MLM$'!4R"1$DKA[
M*X<!J>".<.7CT>N\11^>)> ?QL3L=*&HM=DY(V3)_!*OX[Q:-_EIA4/\L)+]
MK;5R.@F@;IU"*WP8C#1PT:N25ZK5\?Q1NGJMG2&R=YJ^-48RR$S,!+F7AQ%"
MJJB@V!_#W4\8-\)6 ^]5:"'&?-!)K<:#=Y(T[8JVXG3=8.J_+B@&:<*AK TP
M1"'1%0Y63_G:]"PDQ03K60?;\78ZNWY<OQ" K,Z3D_6,W<WW;N#KF^H^T^J/
M#QQ&B"^;FX"DSN$;AVEO=*RW<H^DB^1S_0?L<7@/B)!NMF;]; G]#<Y0OGNF
M9!R.4[($7KIC&C98N$*MAUU-Z>T@OUH9?04&#0V;&V'#J$1-HW,#ME),=$)7
MV.>D'Z4YKP%%7<MF2'8GXSJCRS@NZ=LOX&+A!701PK7"K?$VR!0Q'+%;&F&S
MSQZ5<'=-U QY\8>,O\#-[&PJ.SZ:W'NL;66!M#IEH'EN2384S(KK[T6Y@+LZ
M7;>(@?*VF'[D0/W?,BZ%29Z#A8,:*>T@UOO:]!O456P@:]Y-)X!T<DY7TCE:
M61:MQ+-AQW#A55SMT$T5V98G[V#DFU"G7T'%VKDE8))JK\#EI='=:Q[[!H9.
MNU':C$F*2?,_EM5D O+A=\0@P1[-/\I& T+_EBU63Y)G>5:G9"Y1T=;OTU."
M*[$?>;$\*['C@2B8E&!A5[+2E=P,<3/=&*D>$7(C:[@^@?1R I97W "]? N@
MW%:WY V(<L32Z/"+I8U]0C')OI$8+WJOOF1;3KO3;'F>78"K]+8J/UJN_3L8
MU9>(<8)L.QYMFY72-:G)+ "+H-V!"]C%.TM%[N(@-7EEW]DQ\*";X16[*?S*
MS< [<(4Y)W'@4PL&3VRDGM4N_3YRY-W:(:[A]'5^!L+RU6*5SPHM:W]EJ\C?
M@[G@@OR2ENJD_[*/^5+SFS)DGF?,IV:^/(-\<FHU>@ <&S:5(EE5J]9#!>1N
MSNP\GR'P5RKHH-Q23T!P>PV$X,I![&=-ASBC'X!]^[3))=94_;5>.M0VWI[4
M?.J:!6K!+AH'>+>=8Y MW_ABOP*[@5MK?\.^J_=25.U[N3Y?K 7*,,=BB*5K
M+\:)]15BG4@M]T"N+^BE=@%=H_%#P$6$5ZG/LJ7V.7OC,GR;SM_D$.5>H(U#
M(BP:!>DJPS0J(3$++=G"NJ<R#WHR?6^J[2$)."@S,[U[H2;OWHDJM[1IGXQ'
M\C/%<WQ>0/H#J'?%:RWM&HAF!?86VH@/'#<<1%_="O+0X?@ ;FZ?_NZ[;LC<
M:3"\KJ8?[ZU7:C+XA@7'[K"+70_A<$')C^(8@3[0Q\K%XMY5M?B"9X=*6;".
M5574D4VU=@$/G[R12A@=F!L4&>OS@CK(  R'@4Y,E(]X?SPR4%_,6UUPLN ;
M 3A5@+^+JV:%(X4^415$ZBL.T)%8EV1AB4;7U'.7QK\"*N/64\.WS]4:<^%X
MDYVXN4 >%XI*66H25'ADP5S7:PQ/ODM9R1UF+X4=1 ZY4*D>):B*[EFF_0?5
MHYLSQV\J'.\LVO%9IW6";9?.GW?)E0XU. -CP5WI> 34+H")Y[+)!4FXDV!T
M3.E[_R<"A:4EB:Y@0ZHZ&U=\B0;'LJ02VE;;^J]\S-O\K6_1@INCI!^I/O@5
M?'NQ]"..\)I.$:!3 +.Y7^]+4[G4Q,:+Z^DG["+?:,\@^CW\=3:@SPG!,*L7
MU.40US2GW%[JP8FT2W,\FM35Q[SV8/](R'E)+:)A/5)0@1''5N'I#&M4R3-<
M386K:,7\*R42R#=+J?Z#P%*KLNFVXIAA=C@-6\S)$.#Y\4"9?!75TS\XT@^J
MR3H>G6!!,!GCW(G)Y>_JCJ"4 $'<4 *US(H%Q;07P%.\(3A%1%B2VA+M4/)]
M+MB+U4KBQ)26EN3KS_/<UGB;OR.V$R'M%4NIONM!Z>/\9X$1%>?UFI)F\45H
MU: K&Q"=.;NQHF'U[>YE+,?XA8=I\E=52/5<?L$>OQ +F=/4K,SP)?"U2=:(
MQ9V&(U&Z(T=J/-3\C/ M=X\CZ:3+AN=#$E" "U-4%DJ&7TB#3?B7;KA)JR/@
MH_>&\\D30<[33\,SKS$#)9Q+$@'$WL9A!7,L-66^JS"26W.W39[;F7MTK;V#
M?:=N<&MTSOQ[6[_K6E)GP_VH_$K7!TB=&/U=K5NJWS-9LWM,! J^K7PU[$W<
M-C<&.>@\XQ@'P?6VVG F4(W<Q+B3EI-!4AZ/KC8"<VA<SY:))7R(;DC1)KG,
M:\9L[!)Y$"J10BT0L=4\JU46#4I8V*X5L+LD#W? ]C%1WP%N_9Q6F2,7D"5'
MP02IM,6ZMPJ1/C9>$-O@=( J&C73]76::Q&<1I'Z.E*EG[K/.A^/0()C"D"
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M"! =K]5+4RSIM"@'TC7?H.E#F\:"B3ZI&E7-QH[W>-035.":[,&,=+.%U.[
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MT?33^_;!/%'Y]/[P_.@W>/'D\LOIP?\!4$L#!!0    ( )&&4EK@;,"&6$$
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M @@+"?$!H:#C"!>@O[DB^WC!MKO[( U3&\ UXF4EF6 2#\]:ZKJR@1K"7\A
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MP@>0R5LD\4\*#9DE"Q\[)FT"C3<4KH_[#^4KRH9$5\\<BQURDH9,'NDB/ZB
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ME',PA&9Y"1,=@;NELZK$F6#61 7C\IS34<HAX/#-*(L (FFI2-.]]69MJ]I
M8VW]-V13VI Y'BKBZ>3AX'#@G'UFR-E7M0*B10977&I(ZOYNLA5CCWFJ!0,D
MPJ[OAN>$Y9]F[.-%#Y41S,AM+#5-*JZYCEA*5271EE>CO]E0]]DIP"7TP6JJ
MXX0,F+ <4\!+[9.ZF7(OBX@B^/@+A%$Z1+%.$8D%64+F*A#*(I25+GAJFLK>
M& SAP81I.FBG_"'N$B0?94,>P:MD\4-HI]Q4@(FY]*%*M+FY"#]+K+%Z*-!U
M0W,EE#M>.*H)!91(BO#!AT+EVAI*KT2Y4A*0783Q*D1]$@E B%9BI"@?;111
M]M K-HI8?FE=F;6BDJ =7:W#G?A^@Z OWAL!O$<E6<FU@D94[^="VIXS870S
M>.MK8=NQ5GIJQPI/38U=N&\#=A/L8I48T'H:E26;K=C+-8NN2 EAS+9ZNV]E
M<4W29 \O4$[]5)3*[D%-,XOZNN82S*SVO<REGD(FH2$Z=I"4<< 6\N^E0RYX
MI0$DE(RMNYAI%LT7VE4EE"HG]1#IVDKE^ "N8$H95LH?IF,T*5"D\9]PL_-Q
MK(NX8U'C2NBC<2%1>&!205)UE;U"3-45?H^D)QG?-T,AG<Q-TU\)"Z)9Y33]
MU##O"! U:RK+>/UP9"2WC$D5*5\/?(G&5N O5$EH^QP*[A_5JH2IUN%KS@B9
M:3HFOV/]:=U'-4]NJ-A7VC,3TS:0WRM5N;AO\CFI)EILLMJMNC 69YF%-Y2W
MY24%#DG4@'']J*E]"LTS=56LT 3_!;N9#])5_$X9T)0D[25N2?ZF%\VP-L+-
M+F7'BRO+?$,I9IDFPGZD!B.90-TN97Y?%S=@/\ZH#]E"?,.Y>Q(,@-PY!8YD
M*J>;*HEU"SD51B%-1+0.U:^GT-4+UZX;Y%HDPW1I_KT$V8>*9B*S;$EQ%;HX
M9&I!V-IE#QTJLLXD?J==JMHHIA$IPLU]1/%0U.]!%=K.*6X(SIH52>7OK\9-
M%UPMB0F,,^MH)69!G6V5RJ]BG2LK@^"ZF-D:NBN&>'AO&@]C:A.'F@+('39I
MEQ?4TYZ#4Y[B/6'&'^_816.T8#,U%75_[06\#YK&-=C;U! )B16?;,]47'0-
M"4Z4C"K^"#<E+I:DAZMA6,H:6U5'\?K,9JZ\BT_ ZZQ&YE7YZS\<Y[F$^AOV
MJ@/>GH4WKX*_6PQ(2M2?G07__;[3'W0OSOO!\<7Y<:=WWCU_$PS>=O!C?]![
M?XP_MH(/[;/N27?PJ15TSD\O>L>==QV0O-KG)\U&%^V E[W.H(V/!A>G\'JW
M'WQL]WIME,[>XC1'G>#-Q0<8OG,2''W"%]4$\ 5^DF%/@NYYT#X^ONB=M&$Y
MP<?NX"TMYZS]L<]C=P".[4$'/YQW/@:?+GK_H,<NW@^"7N=-NW<2#"[HN<M>
M]_RX>WG6H3=AOM.S[O& /L!P^$BO<W$*U[%]_%:-?7SQ[K)]SBO$SV\OSDXZ
MO0 ?A75W>[W.AXOC]M'9IV:C__[H71>&D]DZ_SP^>]_O?N@$?W_?Z_9/NL<&
M'FK-..II!P9LG\%,[WOP=K\[&"#,8=\T/P#9WEHK.+KH7;Q_0PM\USY_VQX,
MVG @ "UZOGWR]_<PE88]KOVDV[]\#[/AHM^?X_+A81@?('#>X57A3P1;^(7^
MXGL#.+!^FQ^ 9P>==Y=GL.H3M?N+7K,!8Q^_[_?E2QAT!V!\!DN +=! O4[_
M$B;14+'0198G$+%G.[DX?H^/]'=;!*,RN &? +1]_KG]IM>!0SV_H&G:L)S>
M@! '1N^_[P[@*0%^#Y#@XKC3P?6UZ/?CLW;W'2R@#6_ _WF4RTZO?W$.B(KO
M'_W=K+_9\ ^3YP"$H?/[2N21W>AY ]C!A^XQ(34MN-_7=P3!@JM1WQ]U$-;X
M@MP6M:#ZG>.5>]?NGN$_VS#HY2>%_,&';AMO3;</EQC&PR,&*C#HGG;A$[Z#
M(]'-[;YY.PA..F>P\-ZG8(<.N_.A>](YYW6KGW9QL;0@WET D&9,/>GA^F')
M/[T;7]_XJ'-ZBNB)]Q\P%W"&D*,[L"\&83?CA. 54V$BN=T!TH8W%Q=,>/OO
M3T^[QUV\GS5(R-,8<@F?WR(F(8EH=\\-*="D_J0#%Y[(\%GW75=?S8]MO!I
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M8YQ8\C=02P$"% ,4    " "1AE):2\=BSLX8   :D@  #@
M@ $     9#DP.# V.&0X:RYH=&U02P$"% ,4    " "1AE):ZC^/)""8  "N
M 0, $               @ 'Z&   9#DP.# V.&1E>#$Q+FAT;5!+ 0(4 Q0
M   ( )&&4EK@;,"&6$$  *8B 0 0              "  4BQ  !D.3 X,#8X
M9&5X-#$N:'1M4$L! A0#%     @ D8926M3RO(QA#P  /3L  !
M     ( !SO(  &0Y,#@P-CAD97@U,2YH=&U02P$"% ,4    " "1AE):*\46
M(7@-  !+)P  $0              @ %= @$ 9#DP.# V.&1E>#DY,2YH=&U0
M2P$"% ,4    " "1AE):F"Z$-3X#  !,"P  $0              @ $$$ $
M<VQD8BTR,#(U,#(Q."YX<V102P$"% ,4    " "1AE):,8C[L7H&  "Y1@
M%0              @ %Q$P$ <VQD8BTR,#(U,#(Q.%]L86(N>&UL4$L! A0#
M%     @ D8926KWA+Z'!!   /RP  !4              ( !'AH! '-L9&(M
F,C R-3 R,3A?<')E+GAM;%!+!08     "  ( /H!   2'P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>d908068d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sldb-20250218.xsd" xlink:type="simple"/>
    <context id="duration_2025-02-18_to_2025-02-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <startDate>2025-02-18</startDate>
            <endDate>2025-02-18</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-341">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-02-18_to_2025-02-18"
      id="Hidden_dei_EntityCentralIndexKey">0001707502</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-352">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-353">2025-02-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-354">Solid Biosciences Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-355">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-356">001-38360</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-357">90-0943402</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-358">500 Rutherford Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-359">Third Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-360">Charlestown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-361">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-362">02129</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-363">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-364">337-4680</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-365">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-366">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-367">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-368">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-369">Common Stock $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-370">SLDB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-371">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-372">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
